Akcie společnosti Six Flags po nehodě na horské dráze v Georgii, při níž zemřel jeden člověk, v pondělním obchodování po skončení hlavní obchodní seance klesly o více než 10 %.
Shares of Six Flags Entertainment plunged more than 10% in after-hours trading Monday following reports of a deadly roller coaster incident at one of its amusement parks in Georgia, marking a sharp reversal from gains during the regular session.
The stock had closed 4.5% higher during regular trading before the after-hours sell-off.
One person died and several others were injured in an incident involving the park's 200-foot-tall Goliath roller coaster at Six Flags Over Georgia in Cobb County shortly before 4 p.m. Monday, according to the report, citing local police.
Police did not provide additional details about the incident, the report showed.
Witnesses told a local news station they saw a man fall from the roller coaster and strike the ride several times. Riders were later seen being evacuated from the roller coaster after it stopped near the top of the ride, the report said.
Six Flags said its park staff and local authorities responded immediately to the incident, adding that it was cooperating fully with the investigation, had temporarily closed similar attractions across its parks and would not release further details out of respect for the family's privacy, according to the report.
The company's shares have fallen 22% year to date.
Elon Musk takes a dig at Waymo's pet collision history and says Tesla Robotaxi has a solution
By
You're currently following this author!
Click to unsubscribe from email alerts.
Elon Musk said Waymo's robotaxis are "pet destroyers."
PATRICK PLEUL/POOL/AFP via Getty Images
Elon Musk took a dig at his robotaxi rival, Waymo, calling the vehicles "pet destroyers," and said Tesla Robotaxi has solved the issue of avoiding stray pets.
During a livestreamed interview at an event hosted by Tesla Owners of Silicon Valley on Saturday, Musk called out Waymo for its reported collisions with animals.
"What a lot of people don't know is that Waymos are like pet destroyers," Musk said, laughing. "Well, maybe Waymo's made some improvements on that front, but they do run over a lot of pets, and we don't want to run over pets."
Waymo has gotten flak over animal collisions before, most notably after its run-in with a beloved bodega cat in a San Francisco neighborhood back in October 2025. The feline, named KitKat, died after it was run over by Waymo's rear right tire, video obtained by The New York Times showed.
That is not Waymo's first collision with an animal.
The National Highway Traffic Safety Administration's Standing General Order requires autonomous vehicle companies like Waymo to report qualifying crashes. NHTSA data showed that between July 2025 and July 2026, Waymo reported at least 9 crashes involving animals, 6 of which Waymo described as domestic animals.
A Waymo spokesperson did not respond to a request for comment.
Tesla's robotaxi service also reported a collision involving an animal during the same time period, but the incident involved a supervised robotaxi. Tesla also operated a smaller fleet, and most of its unsupervised operations were concentrated in one city: Austin.
Musk said during the virtual interview that Tesla Robotaxi will be able to detect roaming pets at night.
"We have these challenges of literally like: gray kittens on a gray tarmac with tar seams at night in low visibility. And it's like, 'Can we not run over the kittens,' type of thing," he said.
Musk added that Tesla will deploy the update, though he did not specify when.
Have a tip on Tesla or Waymo? Contact this reporter via email at [email protected] or Signal at lloydlee.71. Use a personal email address, a nonwork WiFi network, and a nonwork device; here's our guide to sharing information securely.
Read next
Lloyd Lee
You're currently following this author!
Click to unsubscribe from email alerts.
Lloyd Lee is a reporter at Business Insider covering frontier technologies, with a focus on how they're being deployed in the real world and the gaps and tensions that emerge as people, companies, and regulators respond. His coverage has featured autonomous vehicles, EVs, robotics, brain-computer interfaces, and AI.Lloyd's reporting on the progress of Alphabet's Waymo and Tesla's autonomous ambitions was recognized by the San Francisco Press Club with a Bay Area Journalism Award.Before joining Business Insider, he was a local reporter for Almanac News and Palo Alto Weekly, covering housing issues, small businesses, and notable Silicon Valley characters.Lloyd is based in San Francisco.He can be reached via email [email protected], or by phone at 646-768-1630, or Signal at lloyd.71.
Zacks Thematic Screens lets you dive into over 30 dynamic investment themes shaping the future. Whether you're interested in cutting-edge technology, renewable energy, or healthcare innovations, our themes help you invest in ideas that matter to you.
Let’s take a closer look at the ‘Cloud Computing’ theme and analyze a stock within, namely Microsoft (MSFT - Free Report) .
Cloud Computing Overview
Cloud computing refers to the on-demand seamless access of computing resources such as servers, storage, databases, networking, software, analytics, and intelligence over the Internet (the cloud) on a pay-per-use pricing model.
It marks a paradigm shift from traditional on-premises infrastructure storage to remote cloud-based storage facilities and relies heavily on virtualization and automation technologies. Instead of buying, owning, and maintaining physical data centers and servers, organizations access a virtual pool of shared resources from a cloud service provider on an as-needed basis.
This lowers operating costs, increases productivity with greater agility and flexibility, and improves scalability with higher economies of scale.
Microsoft Reassures Cloud Concerns
Microsoft posted strong results in its latest release, with sales up 18% YoY and earnings up 23% YoY. It delivered strong Cloud results, a key benchmark that has been watched closely amid the billions it’s been investing in AI infrastructure.
Microsoft’s Intelligent Cloud results include Azure, its cloud computing platform that provides AI computing power to businesses. Intelligent Cloud revenue came in at $39.3 billion, beating our consensus estimate handily and growing at an accelerated rate of 32% YoY.
Bottom Line
Thematic investing has emerged as a powerful way for investors to sync their portfolios with emerging trends. A mix of long-term and short-term themes is increasingly dictating which companies lead as economies expand and markets shift.
While stocks in each theme aren't direct recommendations, they offer a solid starting point. Leverage the Zacks Rank and other metrics to identify the best stocks for your strategy. Each featured stock comes with a Zacks report, giving you the tools to analyze performance and potential.
The Cloud Computing thematic list, which currently includes Microsoft (MSFT - Free Report) , focuses on technology companies that provide the related hardware and software to enable cloud computing services, the communication service providers that offer the network facilities and the various firms that utilize the services across diverse sectors like financial, consumer discretionary and industrials.
Odhady předpokládají, že tržby AMD ze serverových CPU mohou v roce 2027 překročit 50 miliard USD, tažené silnou poptávkou po prémiových serverových procesorech.
SummaryAdvanced Micro Devices is experiencing explosive growth in both AI GPU and premium server CPU markets, now leading in high-end server CPUs. Recent forecasts project AMD's CPU server sales could exceed $50 billion in 2027, with consensus revenue and EPS estimates rising sharply. AMD's AI data center revenues are accelerating, driven by major deals with OpenAI, Meta, and Anthropic, supporting a path to $30+ EPS by at least 2028. With gross margin expansion to 60%, AMD could achieve $40+ EPS and a $1,200 stock price based on 2029 numbers, making shares attractive at current levels. This idea was discussed in more depth with members of my private investing community, Out Fox The Street. Learn More » Getty Images
Advanced Micro Devices, Inc. (AMD) already had a booming AI GPU business, but the CPU server demand continues to skyrocket. While AMD trails Nvidia (NVDA) in the AI GPU space, the company is
56.76K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Akcie společnosti Shopify během pondělní seance vzrostly téměř o 5 % poté, co analytici Cantor Fitzgerald zvýšili cílovou cenu ze 145 USD na 158 USD a ponechali neutrální doporučení.
One of the best and most immediate boosts for a stock is a meaty price target increase by an analyst. That was the case with Shopify (SHOP +4.90%) on Monday, as such a lift helped improve investor sentiment on the online commerce facilitator. Its share rose by almost 5% that trading session as a result.
A 9% bump The researcher responsible for that increase was Cantor Fitzgerald, which now believes Shopify can reach $158 per share. Previously, its fair value assessment was $145. Cantor Fitzgerald didn't become notably more bullish because of this, however, as it maintained its neutral recommendation on the stock.
Image source: Getty Images.
The firm updated its take on Shopify in advance of the company's third-quarter earnings release, slated for Tuesday, Nov. 3. According to reports, it expects the company to notch convincing beats on gross merchandise volume (GMV) and revenue, with the latter's growth coming in at the low 30% range.
That optimistic outlook is tempered by concerns about Shopify's artificial intelligence (AI) inference costs, which might be considerable and squeeze the company's margins. Cantor Fitzgerald also cautioned about Shopify's tilt toward merchant solutions, which are less profitable as a whole than the company's subscription solutions.
Premium Feature
Moneyball Superscore
87/100
Today's Change
(
4.90
%) $
8.37
Current Price
$
179.22
Is it really good to be the king? To me (and many investors), Shopify is the undisputed king of online e-commerce facilitation. Its top line continues to expand impressively in a world where digital retailing isn't just a good idea, it's a necessity.
But there are downsides to the stock, and I feel that market players are right to be concerned. Profitability has been choppy, and valuations are very high for such bottom-line inconsistency. While the company surely has a prosperous future ahead, the stock looks pricey -- particularly after its recent surge.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Shopify. The Motley Fool has a disclosure policy.
Akcie Cloudflare (NET) uzavřely na 350,87 USD po denním poklesu o 2,79 %. Trh očekává čtvrtletní EPS ve výši 0,35 USD a tržby ve výši 733,3 milionu USD.
Cloudflare (NET - Free Report) closed the most recent trading day at $350.87, moving -2.79% from the previous trading session. This change lagged the S&P 500's 0.06% loss on the day. At the same time, the Dow added 0.38%, and the tech-heavy Nasdaq lost 0.44%.
Heading into today, shares of the web security and content delivery company had gained 17.75% over the past month, outpacing the Computer and Technology sector's gain of 4.85% and the S&P 500's gain of 2.36%.
The investment community will be paying close attention to the earnings performance of Cloudflare in its upcoming release. The company's earnings per share (EPS) are projected to be $0.35, reflecting a 29.63% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $733.3 million, reflecting a 30.47% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $1.26 per share and a revenue of $2.87 billion, demonstrating changes of +35.48% and +32.54%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Cloudflare. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. At present, Cloudflare boasts a Zacks Rank of #3 (Hold).
Looking at valuation, Cloudflare is presently trading at a Forward P/E ratio of 285.51. This signifies a premium in comparison to the average Forward P/E of 20.96 for its industry.
Meanwhile, NET's PEG ratio is currently 7.64. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Internet - Software industry stood at 1.21 at the close of the market yesterday.
The Internet - Software industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 94, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Akcie společnosti Harmony Biosciences v pondělí klesly o více než 5 % poté, co firma oznámila, že Peter Anastasiou od 1. ledna 2027 nahradí Jeffreyho Dayna ve funkci generálního ředitele.
Harmony Biosciences (HRMY -5.09%) is getting a new leader, but investors aren't happy about it. On news of a major C-Suite change, they eagerly sold shares in the pharmaceutical company to leave it with more than a 5% loss on Monday.
New boss incoming
That morning, Harmony announced that its current COO and member of its board, Peter Anastasiou, is to become CEO, effective Jan. 1, 2027. In a planned succession, he will replace the healthcare company's current chief, Jeffrey Dayno, who will stay with Harmony in an advisory role throughout that year.
Image source: Getty Images.
In the press release announcing the move, Harmony signaled a "steady as she goes" approach. The company stated that it will stick with its current strategic priorities, including further development of its molecule, pitolisant (approved by the Food and Drug Administration under the brand name Wakix for certain sleep disorders), and advancement of its pipeline.
In addition to detailing the CEO change, Harmony also reiterated its full-year net revenue guidance for Wakix. The drug should maintain its blockbuster status, with net revenue of $1 billion to $1.04 billion. The company added that its assumptions for hitting key commercial and pipeline milestones remain unchanged.
Premium Feature
Moneyball Superscore
74/100
Today's Change
(
-5.09
%) $
-2.05
Current Price
$
38.23
Rite of passage?
Personally, I'm not seeing much in that press release to be gloomy about.
That said, change can be hard for investors, particularly when an outgoing CEO has led a company to success -- as in the case of Dayno, who deserves significant credit in the development of Wakix (he was chief medical officer at the time). I'd probably take this opportunity to load up on the still high-potential Harmony at a discount.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
In the latest trading session, SentinelOne (S - Free Report) closed at $25.66, marking a -2.32% move from the previous day. This move lagged the S&P 500's daily loss of 0.06%. Meanwhile, the Dow experienced a rise of 0.38%, and the technology-dominated Nasdaq saw a decrease of 0.44%.
Shares of the cybersecurity provider witnessed a gain of 33.01% over the previous month, beating the performance of the Computer and Technology sector with its gain of 4.85%, and the S&P 500's gain of 2.36%.
Market participants will be closely following the financial results of SentinelOne in its upcoming release. The company's upcoming EPS is projected at $0.09, signifying a 28.57% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $310.03 million, indicating a 19.74% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $0.32 per share and a revenue of $1.2 billion, demonstrating changes of +60% and +20.32%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for SentinelOne. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.88% lower within the past month. Currently, SentinelOne is carrying a Zacks Rank of #3 (Hold).
Looking at its valuation, SentinelOne is holding a Forward P/E ratio of 83.02. This expresses a premium compared to the average Forward P/E of 59.11 of its industry.
One should further note that S currently holds a PEG ratio of 1.8. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Security industry stood at 3.27 at the close of the market yesterday.
The Security industry is part of the Computer and Technology sector. Currently, this industry holds a Zacks Industry Rank of 102, positioning it in the top 42% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow S in the coming trading sessions, be sure to utilize Zacks.com.
When Space Exploration Technologies (SPCX +0.52%) went public in June, it was at a market cap of $1.75 trillion, immediately making it one of the 10 largest public companies in the world. The common read was that it was overvalued, with Morningstar valuing it at $780 billion.
Ark Invest CEO Cathie Wood disagreed. She has invested heavily in SpaceX, and in a Sept. 16 post on X, she argued that the space company could be a deep-value opportunity at its IPO price.
Image source: The Motley Fool.
The math behind Cathie Wood's valuation
Wood and Ark analyst Sam Korus have provided calculations showing why SpaceX is a deep value, based on Starlink's revenue potential. As of 2025, Starlink generated about $19 million in annual revenue per terabit per second (Tbps) of network capacity. Each Starship carrying 60 Starlink V3 satellites adds about 61 Tbps of capacity, meaning each launch could theoretically generate $1 billion in recurring annual revenue.
SpaceX CEO Elon Musk has set a goal of 10,000 Starship launches per year by 2030. In her post on X, Wood explained that at $1 billion per launch, 10,000 flights would be $10 trillion in annual revenue.
Musk had a short reply: "It's not impossible." While that's true, Musk is known for setting extremely ambitious goals, and this one is worth a reality check.
Flaws in the argument
There are several issues with this $10 trillion revenue projection for SpaceX. The biggest: The space company is nowhere close to 10,000 Starship launches per year. The first Starship launch was in 2023, and to date, there have been 14 total, including nine successes and five failures. Even across SpaceX's fleetwide flights, the total is 165 launches in 2025 and 116 so far this year (as of Oct. 8).
Today's Change
(
0.52
%) $
0.85
Current Price
$
163.42
SpaceX's launch cadence is impressive, as it accounts for about 80% of all U.S. orbital launches, according to recent research by The Motley Fool. But going from less than 10 Starship launches per year to 10,000 by 2030 doesn't seem realistic.
Wood's calculations also assume that every flight carries Starlink satellites and revenue per terabit holds, neither of which is likely. The 10,000-flight goal could include passenger transport, in which case it wouldn't be exclusively satellite payloads. Revenue per terabit is already declining, from $23 million in 2024 to $19 million in 2025.
SpaceX doesn't look like a deep-value stock
SpaceX was richly valued at its IPO price, and it has only gotten more expensive. With a market cap of $2.2 trillion, it trades at about 102 times trailing sales. For perspective, Nvidia has a trailing price-to-sales (P/S) ratio of 19, and even Palantir Technologies, which is anything but a value stock, is cheaper at 83 times sales.
Wood's valuation of SpaceX is based on an extremely optimistic scenario years in the future. Right now, SpaceX is highly volatile and trading at a multiple several times higher than most tech companies.
Before investing, it's worth considering the worst-case scenarios, such as multiple compressions during a bear market, just as thoroughly as the best-case scenario.
Netflix is planning what could be its largest round of layoffs in four years, according to media reports.
The job cuts are expected to impact 5% of the streaming giant’s workforce, with the announcement reportedly coming as soon as this week. Netflix reported 16,000 employees at the end of last year, meaning some 800 people could be laid off.
The rumored layoffs were first reported by Puck news and later confirmed by the Los Angeles Times and other outlets.
Netflix declined to comment.
Subscribe to the Daily newsletter.Fast Company's trending stories delivered to you every day
Mass layoffs have been relatively rare at Netflix, though they have been a common story in the tech industry more broadly this year.
A recent analysis from outplacement firm Challenger, Gray & Christmas found that technology companies announced 165,925 job cuts from January through September 2026, a 54% increase over the same period in 2025.
Netflix last had a large round of layoffs in 2022, when it laid off 3% of its staff.
Bank of America očekává ve 3. čtvrtletí meziroční pokles poplatků z investičního bankovnictví o něco více než 10 % a stagnaci výnosů z obchodování; klíčový bude výhled čistého úrokového výnosu.
Bank of America (BAC +0.48%), the second-largest bank in the U.S. by assets, will report its third-quarter earnings results on Wednesday, Oct. 14, before the market opens. Management, led by CEO Brian Moynihan, will then host a live conference call with Wall Street analysts.
Banks had been benefiting from market rotation earlier this year, but have come under pressure more recently due to soaring bond yields, which increase funding costs and can weigh on loan growth and credit quality.
Banks, including Bank of America, are now widely underperforming the broader market this year. Is Bank of America stock a buy ahead of its third-quarter earnings report?
Image source: The Motley Fool.
Likely will come down to Net Interest IncomeHeading into third-quarter results, Bank of America has lowered expectations for some of its businesses, including investment banking and trading.
At a conference in mid-September, Moynihan told analysts that investment banking fees could be down 10% year over year, while trading revenue may come in flat.
"What we're seeing is the market generally in investment banking is down 10%," said Moynihan, referencing data from Dealogic, according to CNBC. "We're not as well positioned in some of the businesses that have more activity, so we'll be down probably a bit more than that."
So this will likely put net interest income (NII) into focus. NII is the spread revenue that banks earn between what they pay on interest-bearing liabilities, such as deposits, and what they accrue on interest-earning assets, such as loans. It's a key revenue driver for most banks.
On the second-quarter earnings call, Bank of America's CFO Alastair Borthwick told analysts to expect full-year NII to be toward the upper end of its previous guidance of 6% to 8% annual growth.
Borthwick said that's based on modest loan and deposit growth and one rate hike in 2026. However, there's already been one rate hike, and there still could be another.
Premium Feature
Moneyball Superscore
76/100
Today's Change
(
0.48
%) $
0.26
Current Price
$
54.58
Bank of America is asset-sensitive, meaning NII should benefit in a rising-rate environment because assets will reprice faster than liabilities, especially its large, low-cost deposit base, which should see a more modest increase in deposit pricing.
Bank of America is known for having one of the strongest, if not the strongest, deposit bases from a funding perspective, meaning it tends to have a more stable, lower-cost deposit base than its peers.
How funding costs are impacted by soaring bond yields will be very important for Bank of America's NII guidance and how investors treat the stock.
Trying to make a call on a stock before any near-term event is difficult, as one can never know how the market will interpret an earnings report.
Given that management has set a lower bar for investment banking and trading, I think the focus will be on the NII guide. If the bank can maintain or even raise its guidance, then the stock should react well.
Investors will also be razor-focused on credit quality, which has been quite benign. Any significant deterioration could send the stock lower.
Long term, however, I would still rate Bank of America a buy ahead of earnings. The company still has significant scale in many different banking businesses that will be hard to replicate.
The sell-off over the past month has also brought down the valuation and made the stock more attractive in the long term.
General Motors chce v roce 2028 uvést systém řízení, který nebude vyžadovat sledování vozovky ani držení volantu, nejprve v elektrickém Cadillacu Escalade IQ.
General Motors CEO Mary Barra said the automaker is still on track to introduce "eyes-off, hands-off" driving technology by 2028, starting with the electric Cadillac Escalade IQ.After abandoning its Cruise robotaxi business, GM is focusing on autonomous technology for personal vehicles.General Motors CEO Mary Barra said Monday that the automaker remains on track to introduce "eyes-off, hands-off" driving technology by 2028.
GM announced last October that it plans to launch its next-generation driver-assistance system in the electric Cadillac Escalade IQ in 2028 before expanding to other models. Unlike the company's existing Super Cruise system, which allows drivers to take their hands off the wheel but requires them to remain attentive, the new technology is designed to let drivers take their eyes off the road under certain conditions.
Barra told CNBC's Jim Cramer on "Mad Money" that she recently tested the technology and was impressed by how much it had improved since an earlier ride in March. "They're making so much progress on our goal to have eyes off, hands off in the '28 time frame," the CEO said. "We're going to be well positioned from a personal autonomy perspective." She added, "When people want to drive, they can. When they don't, they won't need to as that grows."
GM's push into personal autonomous driving follows its decision to abandon its Cruise robotaxi business in December 2024 after spending more than $10 billion. Rather than compete in the increasingly crowded driverless ride-hailing market, the automaker redirected its resources toward developing autonomous systems for vehicles consumers own. "We're not in the taxi business. We're not in the bus business," Barra said.
She acknowledged that exiting the robotaxi market was difficult but defended the move, noting that GM retained much of the Cruise team to work on personal autonomous driving. "It was a tough decision, but I think it was the right decision," she said.
Barra also pushed back against the idea that widespread adoption of autonomous vehicles could eventually reduce the need for personal car ownership. She recalled earlier predictions that ride-hailing services such as Uber and Lyft would sharply reduce vehicle sales, something that never materialized because "people still value that it's in my driveway. I can go wherever I want, whenever I want."
Whitney Tilson považuje akcie McDonald’s za mírně podhodnocené: obchodují se za 17,6násobek očekávaného zisku v příštím roce, což je pod historickým průměrem 19,7násobku.
McDonald’s Corp (NYSE:MCD) stock has fallen to four-year lows. A former hedge fund manager says the valuation of the stock looks good at current levels and calls shares "undervalued." Here’s why.
• McDonald’s stock is trading near recent lows. What’s the outlook for MCD shares?
Sizing Up McDonald’s StockFormer hedge fund manager Whitney Tilson recently took a look at McDonald’s stock and compared the current valuation and thesis to when he looked at the stock back in June.
"With the stock down another 14% since then, might it now be an especially good buying opportunity?" Tilson asks in a newsletter.
Tilson highlights several strengths of McDonald’s, including boosted margins through franchising, free cash flow doubling since 2018 and strong shareholder returns through share buybacks and a 3%+ dividend yield.
"Over the past two decades, revenues have barely moved. But that’s mostly because McDonald’s has franchised many company-owned units, which reduces capital intensity and boosts profits."
McDonald’s growth has slowed in recent quarters, which may be contributing to the declining stock price. Tilson highlights global comparable sales being up 5.7% in the fourth quarter of 2025, up 3.8% in the first quarter of 2026 and up 1.3% in the second quarter of 2026. The market expert says this is what makes McDonald’s a "slow-growing cash cow."
"McDonald’s is an excellent business, with high margins and robust FCF."
Tilson doesn’t ignore the challenge of restaurant stocks from weight-loss drugs, but sees the valuation of McDonald’s stock too cheap to ignore.
"McDonald’s trades at 17.6 times consensus analysts’ estimates for next year. That’s slightly below its historical average price-to-earnings of 19.7 times over the past quarter century."
Tilson called McDonald’s stock fairly valued back in June. He reaches a different conclusion this time.
"Today, I think it’s moderately undervalued."
Read Next
Tilson’s History with McDonald’s StockTilson previously owned McDonald’s stock in late 2002, a position that he admits he later "backed up the truck" for by adding more shares in early 2003 when they were under $13.
At one time in 2003, the stock was around 10% of Tilson’s hedge fund.
"It was the biggest win of my early investing career," Tilson said.
The investor recalls shares doubling two years after 2003.
In a five-year time period, Tilson watched McDonald’s shares go from under $13 to the mid-$60s.
He later sold the stock during the bear market in 2008, recalling that McDonald’s was one of only two stocks in the Dow Jones Industrial Average that were positive that year, with Walmart being the other.
Tilson said this ended up being a mistake.
"I should have ‘let my winners run’ – the key to long-term investment success, as I’ve written many time."
McDonald’s stock hit $200 by 2019 and $300 by 2024, before peaking at $341.75 in March 2026.
Time will tell if Tilson is right about McDonald’s stock again, but the fact that shares trade at four-year lows does offer an interesting entry point for investors.
Akcie společnosti American Express od začátku roku do 8. října klesly o 18 %, přesto společnost potvrdila výhled zisku na akcii (EPS) pro rok 2026 ve výši 17,30 až 17,90 USD.
It's been a tough year for American Express (AXP +1.09%). Shares have fallen 18% in 2026 (as of Oct. 8). The overall market, on the other hand, has advanced 14% this year.
The financial stock currently sits at about $302 per share, which is only 4% above its 52-week low from March. That's also below the average price of $315.77 that the leadership team paid to repurchase 7.1 million shares during the second quarter.
Does this mean that American Express is a smart buying opportunity right now? Here's how investors should make sense of the situation.
Image source: The Motley Fool.
The business buys back shares every quarter
During the three months that ended June 30, American Express spent $2.2. billion in total on stock buybacks. At the end of Q2, the diluted outstanding share count was 3% lower than a year ago. Investors appreciate this trend, as it provides a lift to earnings per share (EPS).
Now that the stock price is below what management paid, astute investors are wondering whether this is a valuable signal that it's time to add the premium credit card enterprise to their portfolios. The company's executive team should have a firm grasp of the intrinsic value. Repurchasing shares should be done at attractive stock prices. This suggests that shares could be even more undervalued today.
But it's important to take a step back and realize that American Express is a perennial share repurchaser. It bought back $1.7 billion worth of stock in the first quarter, after repurchasing $5.3 billion all of last year. During Q4 2025, when the shares reached a record high, the company still spent $899 million repurchasing shares.
The activity does fluctuate. In recent years, buybacks have been highest in the third quarter, with much less repurchasing happening in Q4. In Q3 last year, for instance, American Express spent $2.5 billion buying back stock at its then-all-time high. It's hard to make any definitive conclusions.
Premium Feature
Moneyball Superscore
86/100
Today's Change
(
1.09
%) $
3.36
Current Price
$
311.53
Think about the next five years
I believe investors should spend more time focusing their attention on what the future will bring. Think about American Express through the lens of a potential long-term investment. Although the stock is down 18% this year, the underlying business is still operating at full strength.
The company raised its quarterly dividend in March by 16%. And it maintained 2026 EPS guidance within a range of $17.30 to $17.90, equating to a 14% increase (at the midpoint) year over year. These are signs of a healthy business that's performing well amid an uncertain macroeconomic environment.
It might be a smart idea to buy the dip on American Express.
American Express is an advertising partner of Motley Fool Money. Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends American Express. The Motley Fool has a disclosure policy.
In the latest trading session, Snowflake Inc. (SNOW - Free Report) closed at $360.37, marking a -2.31% move from the previous day. This move lagged the S&P 500's daily loss of 0.06%. Meanwhile, the Dow experienced a rise of 0.38%, and the technology-dominated Nasdaq saw a decrease of 0.44%.
Heading into today, shares of the company had gained 12.13% over the past month, outpacing the Computer and Technology sector's gain of 4.85% and the S&P 500's gain of 2.36%.
Market participants will be closely following the financial results of Snowflake Inc. in its upcoming release. The company is expected to report EPS of $0.6, up 71.43% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $1.65 billion, up 36.11% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.21 per share and a revenue of $6.3 billion, representing changes of +76.8% and +34.53%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Snowflake Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 2.52% increase. Snowflake Inc. is holding a Zacks Rank of #2 (Buy) right now.
From a valuation perspective, Snowflake Inc. is currently exchanging hands at a Forward P/E ratio of 167.03. This signifies a premium in comparison to the average Forward P/E of 20.96 for its industry.
It's also important to note that SNOW currently trades at a PEG ratio of 5.55. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. SNOW's industry had an average PEG ratio of 1.21 as of yesterday's close.
The Internet - Software industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 94, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Akcie First Solar za poslední měsíc klesly o 14,93 %. Společnost by měla v nadcházejících hospodářských výsledcích vykázat zisk na akcii ve výši 4,64 USD a tržby ve výši 1,31 miliardy USD.
First Solar (FSLR - Free Report) closed at $179.72 in the latest trading session, marking a +1.07% move from the prior day. This change outpaced the S&P 500's 0.06% loss on the day. At the same time, the Dow added 0.38%, and the tech-heavy Nasdaq lost 0.44%.
The stock of largest U.S. solar company has fallen by 14.93% in the past month, lagging the Oils-Energy sector's gain of 1.73% and the S&P 500's gain of 2.36%.
The investment community will be closely monitoring the performance of First Solar in its forthcoming earnings report. The company is forecasted to report an EPS of $4.64, showcasing a 9.43% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $1.31 billion, showing a 17.68% drop compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.68 per share and revenue of $5.06 billion, indicating changes of +24.42% and -2.99%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for First Solar. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.48% downward. Right now, First Solar possesses a Zacks Rank of #3 (Hold).
Looking at valuation, First Solar is presently trading at a Forward P/E ratio of 10.06. For comparison, its industry has an average Forward P/E of 13.59, which means First Solar is trading at a discount to the group.
We can additionally observe that FSLR currently boasts a PEG ratio of 0.48. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Solar industry currently had an average PEG ratio of 0.82 as of yesterday's close.
The Solar industry is part of the Oils-Energy sector. Currently, this industry holds a Zacks Industry Rank of 219, positioning it in the bottom 11% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
TSMC ve třetím čtvrtletí zvýšila tržby o 41 % na zhruba 46,7 miliardy USD, čímž díky poptávce po čipech pro AI překonala vlastní prognózu i očekávání analytiků.
Taiwan Semiconductor Manufacturing Company (TSM -1.98%) is the company behind the world's most advanced semiconductors. The largest third-party chip manufacturer has been one of the biggest beneficiaries of booming artificial intelligence (AI) spending, and that doesn't seem to be slowing down anytime soon.
TSMC's September revenue release showed accelerating sales growth, with the third quarter coming in above management's guidance and analysts' expectations. Here's what's driving the revenue growth for TSMC and why it's my top AI chip stock to buy.
Image source: Taiwan Semiconductor Manufacturing.
What's behind TSMC's rapid revenue growth? TSMC reports monthly sales figures in New Taiwan dollars (NTD) shortly after the end of each month. September sales reached NT512 billion, up 55% year over year. Total third-quarter sales reached NT1.49 trillion, up 51%. However, the New Taiwan dollar lost value relative to the U.S. dollar over the past year, inflating those growth rates. Still, at an exchange rate of 32 NTD to USD, that translates into revenue of about $46.7 billion in revenue for the quarter, up 41% from a year ago and accelerating from 34% growth in Q2.
That number tops both analysts' expectations and TSMC's own internal forecast for revenue between $44.6 billion and $45.8 billion. Management also expected gross margin to come in between 65% and 67% and operating margin between 56% and 58%. Both represent contractions from Q2 but remain close to record levels for the company. We'll have to wait until next week for TSMC to reveal the full earnings results.
Premium Feature
Moneyball Superscore
98/100
Today's Change
(
-1.98
%) $
-8.96
Current Price
$
444.35
There are several significant factors driving TSMC's revenue growth.
First and foremost is the robust demand for AI-related chips. As mentioned, chipmakers rely on TSMC's manufacturing technology to develop the world's most advanced chips, which has led to booming demand for the company.
Second, TSMC quickly ramped up its 2-nanometer (2nm) production process last quarter. The technology accounted for just 3% of revenue in Q2, but that should climb quickly. While that could result in some margin pressure on the business, TSMC is reportedly charging premium pricing for its newest production node, which should offset much of it. What's more, a faster ramp means tooling utilization increases faster, reducing pressure on margins.
Beyond 2nm, pricing is well above existing processes, and management reportedly increased pricing at the start of the year for most of its chips. It plans to continue raising prices every year through at least 2029, with expectations to raise prices 10% at the start of next year.
The last piece of the revenue growth formula is TSMC's massive capacity increases. TSMC has spent heavily on capital expenditure (capex) to meet the demand of AI chip designers that contract with it. That's enabled it to bring more capacity online, and it's actually accelerated its 2nm capacity build-out for 2026. It has plans to spend hundreds of billions on new facilities in Arizona, and it's also exploring building in Texas to diversify from the geopolitical risk of its Asian facilities.
What makes TSMC such a compelling investment is that it's built a wide moat that's enabled it to take market share from competitors despite already dominating the third-party chip manufacturing space. It's unlikely a company like Nvidia or Apple will be able to move a significant amount of work away from TSMC to negatively impact its growth at any point in the future. Nor is it likely they'll want to in the first place.
TSMC benefits from a virtuous cycle. As the world's largest chip fabricator, it generates a large amount of revenue relative to its peers. It can use that revenue to reinvest in research and development and additional capacity. That ensures its technology remains best in class, and it has the capacity to fulfill the growing number of orders from its chip design partners.
Importantly, TSMC is relatively agnostic about who designs the chips it makes. While Nvidia rules the roost today, it might not always be the biggest designer for AI chips. Custom silicon is growing in popularity among the hyperscalers. Regardless of who designs the chips, TSMC will be the company manufacturing them.
That gives me confidence in management's long-term revenue growth outlook of 25% average annualized sales growth between 2024 and 2029. Management is well ahead of that target, and CEO C.C. Wei suggested that number will increase once again when TSMC next updates its guidance.
With Taiwan Semiconductor stock trading for just 27 times earnings, it looks like a bargain. Revenue can grow in the mid-20s for a long time, and earnings growth should significantly outpace that level thanks to price increases protected by its wide moat.
Ithaca Holdings jedná o převzetí společnosti Bumble a jejím vyřazení z burzy za zhruba 1 miliardu USD. Tržby ve druhém čtvrtletí meziročně klesly o 15,2 % na 210,5 milionu USD.
The company is in advanced talks to go private through a newly formed investment firm for roughly $1 billion — a fraction of the more than $14 billion it was worth following its 2021 stock market debut.
Ithaca Holdings, founded by a Sequoia Capital partner and a former Meta executive, could strike a deal as soon as this week, the Wall Street Journal reported Monday.
The negotiations could still fall apart, Bloomberg noted, citing a person familiar with the matter.
Bumble shares jumped about 50% Monday following news of the potential buyout, giving the company a market capitalization of roughly $580 million, up from $335 million at Friday’s close.
Bumble founder Whitney Wolfe Herd is facing a possible $1 billion buyout of the dating app she launched in 2014. AFP via Getty Images
The potential buyout comes as Bumble founder Whitney Wolfe Herd struggles to revive the dating platform amid declining revenue and a shrinking base of paying users.
Wolfe Herd, who co-founded Tinder before launching Bumble in 2014, is expected to remain involved with the company and roll over at least part of her ownership stake as part of the transaction, according to the Journal.
The 37-year-old entrepreneur returned as Bumble’s chief executive in March 2025, a little more than a year after stepping down.
Bumble reported second-quarter revenue of $210.5 million, down 15.2% from a year earlier, while its number of paying users plunged 16.4% to 3.2 million.
Dating app Bumble is in advanced talks to be acquired by newly formed investment firm Ithaca Holdings for roughly $1 billion. Boumenjapet – stock.adobe.com
The company posted a quarterly net loss of $127.9 million and ended June with roughly $154 million in cash.
Bumble in August abandoned its signature requirement that women initiate conversations with male matches, allowing either person to send the first message as the dating app struggled to retain paying customers.
At rival Match Group, Hinge posted a 22% jump in second-quarter revenue, even as the company’s flagship dating app Tinder struggled to regain momentum.
Bumble laid off roughly 30% of its workforce last year, just months after Wolfe Herd returned as chief executive.
Bumble was exploring a possible sale as early as June, with Morgan Stanley advising the company on strategic alternatives, Reuters reported at the time.
A September 2025 Daily Mail investigation alleged that Wolfe Herd mistreated former Tinder colleagues and was physically abusive toward an ex-boyfriend — accusations she denied — while she acknowledged having used racial and homophobic slurs in the past.
Wolfe Herd returned as Bumble’s chief executive in 2025, months before the company laid off roughly 30% of its workforce. REUTERS
Wolfe Herd also came under fire last year from former Tinder executives who disputed her status as a co-founder of the dating app and accused her of exaggerating her contributions to its early success.
Tinder co-founder Jonathan Badeen and former communications executive Rosette Pambakian were among those who challenged her account ahead of the release of “Swiped,” a Hulu film starring Lily James as Wolfe Herd, Page Six reported in September 2025.
Her representatives have previously defended her co-founder title, while Wolfe Herd said she had no involvement in the film.
The Post has sought comment from Bumble and Ithaca.
By You're currently following this author! Click to unsubscribe from email alerts.
Kroger's corporate workforce is going to get leaner. Brandon Bell/Getty Images Kroger plans to cut about 3,000 roles from its corporate workforce over the next three years to simplify operations.
In a memo to staff that the company shared with Business Insider, CEO Greg Foran said the corporate-level reductions will allow Kroger to invest in frontline workers.
"Our business is becoming leaner, more focused and more competitive," he said.
The former Walmart US CEO took the helm of Kroger earlier this year and has set to work cutting prices and tightening operations over the past several months.
Foran also cited the impact of technology on the century-old company, saying that it merits a close look at where work can be done.
Amazon cuts 14,000 corporate jobs amid AI restructuring
Read the memo from CEO Greg ForanFROM: Desk of Greg Foran inboxTO: All companyRE: Changes to Our OrganizationWe shared important information on our all-company call today, and we're following up to make sure everyone is aware of the changes ahead.As a company, we have made great progress on many fronts with our customers. We started reducing prices and improving our customer experience in stores and online, and we made investments in simplifying our associates' lives through technology. Our business is becoming leaner, more focused and more competitive. We are working to be more agile; more precise in our execution; and deliver benefits to our customers, associates and our shareholders.This transformation will also result in fewer roles across the company, which means we will reduce our corporate workforce across many functions, by approximately 3,000 roles over the next three years. These reductions will allow us to continue to invest in our frontline associates.These are difficult decisions, and we do not make them lightly. This is the right thing for the company's long-term future. Here's why:Simplifying our operations is critical. Simplifying means making faster decisions and deploying more resources where they matter most, so that we deliver lower prices and a better experience for our customers. Our company has more layers, more handoffs and more overhead than we need, so we are addressing this issue.Technology is reshaping what's possible. The way work gets done is changing across every industry; we must adapt and take advantage of technology. We need to adopt capabilities, reduce duplicative work and look closely at where work is best fit to be done.We have the opportunity to make changes that will create broader roles and faster decision making. This lets us move vital resources closer to the customer to lower prices, invest in our associates and create a better shopping experience.When and how this will happenThese reductions will take place across multiple years. We will share updates when we can. We expect decisions about impacted roles to start being communicated in the coming months.Our values at workDuring these difficult moments, we will continue to be guided by Our Values. We will communicate directly with impacted associates as we make decisions, and we will not ask anyone to wait longer than necessary for clarity about their roles.We are grateful for each one of you. With the Kroger Leadership Team, we are committed to leading this company through this moment with transparency, integrity and respect.Greg
Read next
Dominick Reuter You're currently following this author! Click to unsubscribe from email alerts.
Dominick Reuter is a senior retail reporter for Business Insider, primarily covering Walmart, Target, Costco, and other big box retailers. His stories tend to focus on issues and trends that affect employees and customers, such as affordability challenges and the growing race to provide ultra-fast delivery services on e-commerce orders.Prior to joining BI in 2019, Dominick worked for more than a decade as an independent photojournalist covering a wide range of stories for global wire services and newspapers, including Reuters, the Wall Street Journal, and Agence France-Presse.Dominick studied photojournalism at Boston University and later earned a Masters in business and economics journalism from Columbia University.If you're an employee or customer with a story to share, please contact me via email or text/call/Signal at 646-768-4750.
CME Group dokončila počáteční testy výkonnosti systému CME Globex v cloudu; migrace trhu s hospodářskými zvířaty do cloudového regionu Aurora je plánována na konec roku 2027.
, /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced it has completed initial performance testing for CME Globex in the cloud, reaching new milestones in the ongoing migration of its markets, including:
Faster round-trip times for trading. Ahead-of-schedule construction of the Aurora Cloud Region and co-location facility. The facility, which will host Google Cloud's new, industry-first specialized platform to support trading of CME Group markets, is targeted to be available for client testing in mid-2027, in addition to the Dallas disaster recovery facility that has been open for testing since June 2026. Livestock market migration to the cloud will take place out of the new Aurora Cloud Region in late 2027. Interim relocation to Dallas is no longer necessary. "We are very pleased to be making faster than anticipated progress on our transition plans to migrate our markets to the cloud," said CME Group Chairman and Chief Executive Officer Terry Duffy. "Given the accelerated timeline on our Aurora Cloud Region as well as strong initial performance testing, we will deliver the first cloud-based solution for ultra-low latency trading sooner than expected. We will work to ensure our clients can access both Google Cloud-managed services and co-location capabilities in Aurora in late 2027."
As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products and metals. The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing.
CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc. CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC ("S&P DJI"). "S&P®", "S&P 500®", "SPY®", "SPX®", US 500 and The 500 are trademarks of Standard & Poor's Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners.
Statements in this press release that are not historical facts are forward-looking statements, provided pursuant to the safe harbor established under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and other factors that might cause the actual performance of CME Group to differ materially from those expressed or implied in this press release and, therefore, should be viewed with caution. Further information on the risks that may affect CME Group's business is included in filings it makes with the SEC from time to time, including those discussed under the "Risk Factors" section in CME Group's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. CME Group assumes no obligation to update any such forward-looking statements.
Wolfspeed, Inc. (NYSE:WOLF – Get Free Report) shares fell 9.1% during trading on Monday. The stock traded as low as $28.08 and last traded at $27.8330. 957,415 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 4,297,762 shares. The stock had previously closed at $30.61.
Analyst Upgrades and Downgrades A number of equities research analysts recently weighed in on WOLF shares. Wall Street Zen cut Wolfspeed from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 19th. TD Cowen reiterated a “hold” rating and issued a $25.00 target price on shares of Wolfspeed in a research note on Thursday, August 20th. Susquehanna cut their target price on Wolfspeed from $40.00 to $30.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 21st. Weiss Ratings upgraded shares of Wolfspeed from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday. Finally, Zacks Research upgraded shares of Wolfspeed to a “hold” rating in a report on Friday, September 25th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $25.00.
View Our Latest Research Report on Wolfspeed
Wolfspeed Price Performance The stock’s 50-day moving average is $28.11 and its 200 day moving average is $35.21. The company has a market cap of $1.44 billion and a PE ratio of -1.72. Wolfspeed (NYSE:WOLF – Get Free Report) last announced its earnings results on Wednesday, August 19th. The company reported ($2.26) earnings per share for the quarter, beating the consensus estimate of ($2.45) by $0.19. The firm had revenue of $149.60 million during the quarter, compared to analyst estimates of $150.00 million. During the same quarter last year, the business earned ($0.77) earnings per share. Wolfspeed’s revenue was down 24.1% on a year-over-year basis. On average, analysts expect that Wolfspeed, Inc. will post -8.27 EPS for the current year.
Institutional Trading of Wolfspeed Institutional investors have recently made changes to their positions in the business. FNY Investment Advisers LLC purchased a new position in Wolfspeed during the 2nd quarter worth $204,000. AXQ Capital LP acquired a new position in Wolfspeed during the 2nd quarter valued at about $208,000. Concurrent Investment Advisors LLC acquired a new position in Wolfspeed during the 2nd quarter valued at about $229,000. Royal Bank of Canada purchased a new stake in Wolfspeed in the first quarter valued at about $89,000. Finally, WINTON GROUP Ltd purchased a new stake in Wolfspeed in the second quarter valued at about $299,000.
Wolfspeed Company Profile (Get Free Report)
Wolfspeed, Inc (NYSE:WOLF) develops and manufactures semiconductor technologies based primarily on silicon carbide, a wide-bandgap material designed to support efficient power conversion and high-temperature operation. Its products are used in applications where reduced energy loss, higher power density and improved thermal performance are important.
The company’s offerings include silicon carbide wafers and materials, power modules, metal-oxide-semiconductor field-effect transistors (MOSFETs), diodes and other power semiconductor devices.
See Also Five stocks we like better than Wolfspeed China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit 3 REITs That May Win in a Higher Interest Rate Environment Broadcom’s Anthropic Bet Gets Bigger as $60 Billion Financing Raises the Stakes Insider Buying Signals Opportunity in H.B. Fuller, FocalTherics, Cardinal Receive News & Ratings for Wolfspeed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wolfspeed and related companies with MarketBeat.com's FREE daily email newsletter.
Akcie společnosti Lumentum v pondělí klesly o 9,8 % poté, co šéf společnosti Broadcom vyjádřil pochybnosti o udržitelnosti a ziskovosti současných investic do umělé inteligence.
Shares of optical leader Lumentum (LITE -9.78%) sank on Monday, falling 9.8%.
Lumentum has been a key beneficiary of the AI build-out, as optical lasers are increasingly important for achieving the speeds required for AI training and inference. Last week, Lumentum CEO Michael Hurlston said in a Bloomberg interview that the company was "almost sold out" for 2029, sending shares to an all-time high.
However, concerns over the sustainability of the AI boom came to the fore over the weekend when another AI company CEO said many investors are treating it like a "casino."
Premium Feature
Moneyball Superscore
82/100
Today's Change
(
-9.78
%) $
-107.95
Current Price
$
995.41
Broadcom CEO Hock Tan curbs AI enthusiasm
Over the weekend, Broadcom (AVGO -1.88%) CEO Hock Tan spoke at an industry conference in Singapore. At that conference, he said many investors don't really know what they are investing in, and that they, "set very extreme expectations only to find out that it's almost like they are in a casino."
Tan went on to note that while leading AI companies, such as OpenAI, are generating significant revenue at the moment, it remains unclear whether they will have a sustainable, profitable business model that justifies the enormous amount of current AI spending. He noted that enterprises are using many AI tokens, but mostly in an experimental manner that isn't necessarily economical in the long run:
When you are a kid, you go to a video arcade and play. Your parents give you $10 of tokens, you finish it in 10 minutes and you haven't learned anything... That's what happening in enterprises today."
Those comments appeared to generate a big pullback in the main AI infrastructure stocks on Monday. Given that Lumentum has been one of the big winners, surging to all-time highs last week, it's no wonder its stock is down even more than other chip stocks today.
Image source: Getty Images.
Lumentum's bull case remains as long as the AI story remains as well
Optical laser stocks have rallied so much this year because the network requirements of AI usage are spurring not only an increase in the number of data centers, and communications between those data centers, but also the replacement of copper wiring by optical connections within server racks and even servers themselves.
This compounding growth is why optical stocks remain attractive; however, this depends on the overall health and need for AI data centers. Hock Tan threw some cold water on the growth thesis over the weekend, but his statements were far from declaring the AI build-out a "bubble" that will inevitably burst. The bull case could remain intact, as long as end users eventually get value from the technology, and sustainable AI business models are developed.
, /PRNewswire/ -- International Paper (NYSE: IP) (LSE: IPC), today declared a quarterly dividend of $0.4625 per share for the period from October 1, 2026, to December 31, 2026, inclusive, on the common stock, par value $1.00, of the Company, payable on December 15, 2026, to holders of record at the close of business on November 16, 2026.
Today, the Company also declared a quarterly dividend of $1.00 per share for the period from October 1, 2026, to December 31, 2026, inclusive, on the cumulative $4.00 preferred stock of the Company, payable on December 15, 2026, to holders of record at the close of business on November 16, 2026.
About International Paper (NYSE: IP; LSE: IPC)
International Paper creates sustainable packaging solutions that enable our customers, teammates and shareowners to thrive in an ever-changing world. We are a leader in corrugated packaging, partnering with customers across industries to protect what matters most, strengthen supply chains and create lasting value. Learn more at internationalpaper.com.
Curaleaf zvýšil nabídku na převzetí společnosti Aurora Cannabis ze 4 USD na 5 USD za akcii. Akcie společnosti Aurora Cannabis od první nabídky vzrostly zhruba o 25 %.
There's nothing quite like talk of an acquisition that can send a stock soaring quickly. Aurora Cannabis (ACB -3.12%) stock has been flying recently, as it has benefited from the takeover attempt that Curaleaf Holdings (CURLF -1.49%) launched a few months ago.
In August, Curaleaf announced plans for a hostile takeover of Aurora, after expressing frustration with efforts to pursue a deal privately. Curaleaf is a large multistate operator and one of the largest cannabis companies in the U.S. market, while Aurora is a Canadian-based cannabis company with a growing presence internationally, which is the key attraction for Curaleaf.
Recently, Curaleaf raised its offer for Aurora, in the hopes of swaying shareholders. As a result of the recent offers, Aurora's stock has taken off, rising by around 25% since Curaleaf first announced plans to make a bid. Can it still rise higher, and is now a good time to buy Aurora's stock?
Image source: Getty Images.
Curaleaf raises offer to $5Last week, Curaleaf announced it was going to raise the value of its offer for Aurora to $5. Previously, it had offered $4. Both offers are based on a mix of cash and stock.
Aurora released a press release, urging its shareholders not to take any action and that the company has a special committee which will thoroughly review the offer and provide shareholders with a formal recommendation. It also noted that shareholders won't have to make any decision until Dec. 4 or later, based on the offer's expiry date.
Previously, Aurora was adamant that the offer didn't reflect the company's value sufficiently. Now, however, the Board of Directors is taking the matter more seriously with a committee evaluating the bid.
There is the possibility that the offer ends up being rejected, at which point Curaleaf may raise its offer yet again, or perhaps walk away from the deal.
The last time Aurora's stock was trading at $5 or more was last December. But given the stock's 94% decline over the past five years, long-term investors may not be jumping at the chance to take the deal, particularly if they are hopeful of a better future ahead, with Aurora focusing on expanding into international cannabis markets.
Premium Feature
Moneyball Superscore
43/100
Today's Change
(
-3.12
%) $
-0.14
Current Price
$
4.35
Why I believe Aurora's stock will go higher before the end of the yearIn recent years, Aurora has simplified its business and become less reliant on the Canadian cannabis market and instead focused its efforts internationally. It's still an unprofitable company, and there's a ton of risk here. But with Curaleaf showing a great deal of interest in the business, it's a good sign to investors that there are some quality assets in its portfolio. Curaleaf could have gone for Tilray Brands or Canopy Growth, but it opted for Aurora instead.
I don't think Aurora investors will rush to take the $5 offer simply because the stock is already fairly low with a market cap of around $280 million. Meanwhile, I think the international business is compelling enough for Curaleaf that it will continue to bid higher.
Investors, however, should tread carefully because if that doesn't happen and Curaleaf withdraws its offer, then Aurora's stock could quickly sink back down.
, /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) announced today that preliminary assets under management decreased to $900 billion during September 2026 from $919 billion at the end of August. The 2% decline in month-end AUM was primarily driven by market depreciation, coupled with net outflows during the month. By channel, Institutional generated net inflows, which were partially offset by net outflows in Retail and Private Wealth. For the quarter ended September 30, 2026, preliminary firmwide net inflows totaled approximately $6.0 billion.
AllianceBernstein L.P. (The Operating Partnership)
Assets Under Management ($ in Billions)
At September 30, 2026
Aug 31,
2026
Private
Institutions
Retail
Wealth
Total
Total
Equity
Actively Managed
$
45
$
159
$
62
$
266
$
273
Passive
35
43
12
90
91
Total Equity
80
202
74
356
364
Fixed Income
Taxable
121
61
21
203
206
Tax-Exempt
1
62
32
95
99
Passive
—
17
—
17
18
Total Fixed Income
122
140
53
315
323
Alternatives/Multi-Asset Solutions(1)
181
10
38
229
232
Total
$
383
$
352
$
165
$
900
$
919
At August 31, 2026
Total
$
389
$
361
$
169
$
919
(1) Includes certain multi-asset solutions and services not included in equity or fixed income services.
Cautions Regarding Forward-Looking Statements
Certain statements provided by management in this news release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. The most significant of these factors include, but are not limited to, the following: the performance of financial markets, the investment performance of sponsored investment products and separately-managed accounts, general economic conditions, industry trends, future acquisitions, integration of acquired companies, competitive conditions, and government regulations, including changes in tax regulations and rates and the manner in which the earnings of publicly-traded partnerships are taxed. AB cautions readers to carefully consider such factors. Further, such forward-looking statements speak only as of the date on which such statements are made; AB undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. For further information regarding these forward-looking statements and the factors that could cause actual results to differ, see "Risk Factors" and "Cautions Regarding Forward-Looking Statements" in AB's Form 10-K for the year ended December 31, 2025 or Form 10-Q for the quarter ended June 30, 2026. Any or all of the forward-looking statements made in this news release, Form 10-K, Form 10-Q, other documents AB files with or furnishes to the SEC and any other public statements issued by AB, may turn out to be wrong. It is important to remember that other factors besides those listed in "Risk Factors" and "Cautions Regarding Forward-Looking Statements", and those listed above, could also adversely affect AB's financial condition, results of operations and business prospects.
About AllianceBernstein
AllianceBernstein is a leading global investment management firm that offers diversified investment services to institutional investors, individuals and private wealth clients in major world markets.
As of September 30, 2026, including both the general partnership and limited partnership interests in AllianceBernstein, AllianceBernstein Holding owned approximately 31.1% of AllianceBernstein. Including both the general partnership and limited partnership interests in AllianceBernstein Holding and AllianceBernstein, Equitable Holdings, Inc. ("EQH"), owned an approximate 68.3% economic interest in AllianceBernstein.
Additional information about AB may be found on our website, www.alliancebernstein.com.
Společnost Matson pokřtila kontejnerovou loď Makua, první ze tří nových plavidel v celkové hodnotě přibližně 1 miliardy USD. Má být dodána v prvním čtvrtletí roku 2027.
In the news release, MATSON CHRISTENS NEXT ALOHA CLASS VESSEL 'MAKUA', issued 12-Oct-2026 by Matson, Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
MATSON CHRISTENS NEXT ALOHA CLASS VESSEL 'MAKUA'First of Three New Containerships Will Enter Service in 2027
, /PRNewswire/ -- Matson, Inc. (NYSE: MATX), a leading U.S. carrier in the Pacific, and Hanwha Philly Shipyard, Inc. (HPSI), a leading U.S. shipbuilder of ocean-going merchant vessels, christened the first of three new containerships being built for Matson's China-Long Beach Express (CLX) and Hawaii services in a ceremony at Hanwha Philly Shipyard (HPSI) on Saturday, October 10.
Christening of Matson containership 'Makua' at Hanwha Philly Shipyard, Oct. 10, 2026.
At the ceremony, Matson board member Jenai Wall officially christened the vessel 'Makua' by breaking a ceremonial bottle of champagne against the ship's hull before a gathering of approximately 300 attendees including U.S. Maritime Administration Deputy Administrator Mark Johnson, Matson and HPSI executives, shipyard workers and union leaders. Speakers included U.S. Transportation Command (USTRANSCOM) Deputy Commander Lt. General Jered P. Helwig.
Representing an investment of approximately $1 billion, Matson's three new Jones Act-compliant vessels are being built to match the size and speed of Matson's two existing Aloha Class ships, Daniel K. Inouye, and Kaimana Hila, which were also built by HPSI and set a new standard for cargo transportation in Hawaii when they entered service in 2018 and 2019, respectively, as the largest containerships ever constructed in the U.S.
Weighing in at over 51,400 metric tons, Matson's 850-foot long and 3,600-TEU*-capacity Aloha Class containerships are also Matson's fastest vessels, with a top speed of nearly 24 knots, helping ensure on-time deliveries in Hawaii and industry-leading transit times from Asia to the U.S. West Coast.
Like their sisterships, the new vessels will be equipped with dual fuel engines designed to operate on either conventional marine fuels or liquefied natural gas (LNG), as well as other "green ship technology" features, such as a fuel-efficient hull design, environmentally safe double hull fuel tanks, and freshwater ballast systems. While the earlier ships required some modification to operate with LNG, the new ships will be delivered LNG-ready.
The three new ships will replace three vessels currently deployed in Matson's Hawaii and CLX services. Makua is scheduled for delivery in the first quarter of 2027; the second ship is scheduled to deliver in the third quarter of 2027, and the third is expected in the second quarter of 2028.
"We look forward to putting Makua to work serving our customers early next year," said Matt Cox, chairman and chief executive officer. "We're excited that adding three new Aloha Class ships to Matson's fleet over the next 18 months will improve operating efficiencies and reliability, and increase capacity in our core Hawaii service, as well as our China-Long Beach Express service. And we're proud that building them here supports hundreds of good-paying shipyard jobs and will provide more than 2,500 job opportunities for U.S. mariners over the lifespan of each ship."
HPSI is a leading U.S. commercial shipyard constructing vessels for operation in the domestic Jones Act trade lanes. Prior to Matson's first two Aloha Class ships, the shipyard delivered four newly built Jones Act containerships for Matson between 2003 and 2006.
"Today's christening of Makua is especially meaningful because Matson has been part of the story of this shipyard from its earliest days," said David Kim, CEO of HPSI. "Our partnership spans generations of vessels and reflects a shared commitment to American shipbuilding and the U.S. maritime industry. We are grateful for Matson's continued trust in our people, and incredibly proud of the skill and craftsmanship our workforce is bringing to Makua and the next generation of Aloha Class ships."
Matson plans to name the other two new containerships Malama and Makena. Founded in 1882 as a Hawaii-focused business, Matson has a long tradition of giving Hawaiian names to its vessels serving Hawaii, and also reusing vessel names from the early 20th century.
Matson's original ships named Makua, Malama, and Makena were all freighters commissioned by the United States Shipping Board (USSB), an emergency agency established by the 1916 Shipping Act to increase the number of U.S. ships supporting the war effort during World War I. They were purchased by Matson in the 1920s and remained active in the Matson fleet for the next two decades.
Makua ("mah-KOO-ah") is a Hawaiian word for parent, elder, ancestor, or family.
Malama ("MAH-lah-mah") is a Hawaiian word meaning to care for or protect.
Makena ("Mah-KEN-ah") is a Hawaiian word for abundance.
More information on Makua and Matson's fleet modernization program is available at www.Matson.com.
* TEU = Twenty-foot Equivalent Units, the standard unit of measurement for container capacity
About Matson
Founded in 1882, Matson (NYSE: MATX) is a leading provider of ocean transportation and logistics services. Matson provides a vital lifeline of ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, and Guam, and to other island economies in Micronesia. Matson also operates premium, expedited services from China to Long Beach, California, which includes cargo from other Asia origins, provides services to Okinawa, Japan and various islands in the South Pacific, and operates an international export service from Alaska to Asia. The Company's fleet of owned and chartered vessels includes containerships, combination container and roll-on/roll-off ships and barges. Matson Logistics, established in 1987, extends the geographic reach of Matson's transportation network throughout North America and Asia. Its integrated logistics services include rail intermodal, highway brokerage, warehousing, freight consolidation, supply chain management, and freight forwarding to Alaska. Additional information about the Company is available at www.matson.com.
About Hanwha Philly Shipyard, Inc.
Hanwha Philly Shipyard, Inc. (HPSI) is a leading U.S. shipbuilder with a state-of-the-art shipbuilding facility that has earned a reputation as a preferred provider of ocean-going merchant vessels with a track record of delivering quality ships, having delivered around 50% of all large ocean-going U.S. Jones Act commercial ships since 2000.
The Shipyard is part of Hanwha Group, a multinational company with a robust network of affiliates in the energy, ocean, aerospace, finance, and retail & services industries.
For more information, visit www.hanwhaphillyshipyard.com.
Correction: In the third paragraph the spelling of Kaimana Hila has been corrected.
HHH to Host Earnings Call on November 6, 2026 | Source: Howard Hughes Holdings Inc.
THE WOODLANDS, Texas, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Howard Hughes Holdings Inc. (NYSE: HHH) (“the Company” or “Howard Hughes”) announced today that the Company will release 2026 third quarter earnings on Thursday, November 5, 2026, after the market closes and will hold its third quarter conference call on Friday, November 6, 2026, at 10:00 AM Eastern Time. The Company's earnings release will be posted to the Investors section of the Company's website prior to the conference call.
Please visit the Howard Hughes website to listen to the earnings call via a live webcast. Listeners who wish to participate in the question-and-answer session may do so via telephone by pre-registering on HHH’s earnings call registration webpage. All registrants will receive dial-in information and a PIN allowing them to access the live call. An on-demand replay of the earnings call will be available on the Company’s website immediately following the conclusion of the live call for a period of one year.
About Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc. (NYSE: HHH) is a diversified holding company focused on growing long-term shareholder value. Its principal subsidiaries are Vantage Group Holdings, a leading specialty insurance, reinsurance, and partnership capital platform, and Howard Hughes Communities®, one of the nation’s leading real estate platforms. HHH brings together long-duration capital, high-quality operating businesses, and disciplined capital allocation to build long-term value. For additional information visit www.howardhughes.com.
FormFactor a Teradyne navázaly technologickou spolupráci v oblasti testování čipů nové generace; Teradyne plánuje strategickou kapitálovou investici ve výši 300 milionů USD do FormFactor.
Companies to combine leadership in probe, interface, and test technologies to accelerate AI and high-performance compute deployments | Source: FormFactor, Inc.
LIVERMORE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM), a leading provider of semiconductor test and measurement technologies, and Teradyne, Inc. (Nasdaq: TER), a leading provider of automated test equipment and advanced robotics, today announced the two companies have entered into a broad technology collaboration aimed at accelerating the development, validation, and high-volume production deployment of next-generation semiconductor devices. In addition, Teradyne has agreed to purchase shares of FormFactor common stock.
The collaboration brings together FormFactor’s industry-leading expertise in probe technologies, interface solutions, test engineering, and device characterization with Teradyne’s advanced automated test platforms to help customers address growing semiconductor complexity. Together, the companies will partner to advance semiconductor test architectures, optimize test infrastructure, and enhance production readiness for existing and emerging applications, including high-performance compute (HPC), advanced packaging, high-bandwidth memory (HBM), and silicon photonics.
"The semiconductor industry is entering a period where test performance, scalability, and time-to-market are becoming decisive competitive advantages," said Mike Slessor, Chief Executive Officer of FormFactor. "By combining FormFactor's deep expertise in device characterization, probing, interfaces, and production test solutions with Teradyne's test platforms, we can help customers accelerate innovation and move more efficiently from technology development to high-volume manufacturing."
“The most demanding test challenges in advanced packaging, silicon photonics, and memory can’t be solved by a single company,” said Gregory Smith, President and Chief Executive Officer of Teradyne. “By investing in FormFactor and combining our leading-edge test platforms with FormFactor’s probe and interface expertise, we’re building a more complete, validated path to production for our shared customers, and reinforcing our commitment to an open, interoperable ecosystem.”
The companies believe the collaboration will accelerate innovation across the semiconductor test ecosystem from wafer to data center, expand opportunities for joint customer engagement, and support increasing demand for advanced computing, AI infrastructure, and next-generation semiconductor technologies.
Under the terms of the agreement, Teradyne has agreed to make a $300 million strategic equity investment. The transaction is subject to customary closing conditions and regulatory approvals.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the “safe harbor” provisions of the federal securities laws, including statements regarding the expected benefits and anticipated results of the collaboration between Teradyne and FormFactor, and the anticipated timing and consummation of Teradyne’s investment in FormFactor. Investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements due to known and unknown risks, uncertainties, assumptions, and other factors. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and Teradyne and FormFactor disclaim any obligation to update these forward-looking statements to reflect future events or circumstances.
About FormFactor
FormFactor, Inc. (Nasdaq: FORM) is a leading provider of essential test and measurement technologies along the full IC life cycle — from characterization, modeling, reliability, and design de-bug to qualification and production test. Semiconductor companies rely upon FormFactor’s products and services to accelerate profitability by optimizing device performance and advancing yield knowledge. The Company serves customers through its network of facilities in Asia, Europe, and North America. For more information, visit www.formfactor.com
Investor Relations Contact for FormFactor, Inc.
Stan Finkelstein
Investor Relations
(925) 290-4273 [email protected]
About Teradyne
Teradyne (Nasdaq: TER) designs, develops, and manufactures automated test equipment and advanced robotics systems. Its semiconductor and electronics test solutions span the full AI device supply chain, from wafer to data center, enabling customers to meet the quality and reliability standards the AI era demands. Its advanced robotics business deploys intelligent automation across manufacturing, logistics, and data center operations for customers worldwide. For more information, visit www.teradyne.com.Teradyne® is a registered trademark of Teradyne, Inc., in the U.S. and other countries.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Papa John's To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Papa Johns between August 7, 2025 and August 5, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - October 12, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Papa John's International Inc. ("Papa Johns" or the "Company") (NASDAQ: PZZA) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the true state of Papa Johns' transformation; notably, that it was "taking longer than expected," and ultimately was unable to prevent further market share losses. Papa Johns ultimately required a significant shift in strategy toward a sharp increase in promotional efforts to abate the Company's declining competitive position.
On August 6, 2026, Papa Johns announced an 8.3% decrease in North American comparable sales, the suspension of its dividend, and a sharp reduction in its 2026 outlook from a 3% decline in North American comparable sales at the midpoint to a 7% annual decline. The Company attributed its strategic shift and guidance reset on the soft consumer trends and the execution of Papa Johns' own turnaround efforts, admitting they were unable to "meet the consumer as much as [they] should have," and the rebuilt innovation pipeline was "not bringing in as many new customers" as had been expected.
On this news, the price of Papa Johns' common stock declined dramatically. From a closing market price of $29.75 per share on August 5, 2026, Papa Johns' stock price fell to $24.64 per share on August 6, 2026, a decline of about 17.18% in the span of just a single day.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Papa Johns' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about Papa John's International Inc. class action, go to www.faruqilaw.com/PZZA or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Papa Johns Securities Class Action Lawsuit:
What is the Papa Johns securities fraud lawsuit about?
The lawsuit alleges Papa Johns misled investors about its transformation strategy, including delays in its turnaround, continued market share losses, and the need for increased promotions to address its declining competitive position.
Who may be eligible to participate in the lawsuit?
Investors who purchased or acquired Papa John's International (NASDAQ: PZZA) securities between August 7, 2025 and August 5, 2026 may be eligible if they suffered losses.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff represents the proposed class during the litigation. Eligible investors must file a motion with the court by November 2, 2026. Investors may participate without serving as lead plaintiff.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Papa Johns securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/318559
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
LOS ANGELES, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming November 2, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Papa John’s International, Inc. (“Papa John’s” or the “Company”) (NASDAQ: PZZA) securities between August 7, 2025 and August 5, 2026 inclusive (the “Class Period”).
IF YOU SUFFERED A LOSS ON YOUR PAPA JOHN’S INTERNATIONAL, INC. INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.
What Happened?
On August 6, 2026, Papa Johns issued its second quarter 2026 financial results, reporting an 8.3% decline in North American comparable sales. The Company also reduced its fiscal 2026 outlook, expecting “global system-wide sales to decline between 2% and 4% compared to last year and adjusted EBITDA between $180 million to $190 million,” and suspended its quarterly dividend. During the related conference call, CEO Todd Allan Penegor stated that “it’s clear that our transformation is taking longer than expected” and “we must execute better and move faster.”
On this news, Papa Johns’ stock price fell $5.11 or 17.18%, to close at $24.64 per share on August 6, 2026, thereby injuring investors.
What Is The Lawsuit About?
The complaint filed in this class action alleges that between August 7, 2025 and August 5, 2026, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendants created the false impression that they possessed reliable information pertaining to the effectiveness and ongoing impact of the Company’s strategic transformation as well as their resulting projected growth outlook for the North American region; (2) Defendants also minimized the risk of cautious consumer sentiment, competition woes, promotional seasonality, and more general macroeconomic fluctuation; (3) In truth, Papa Johns’ strategic transformation was taking considerably longer than the projections had suggested and the Company was simply ill equipped to “meet the consumer where they're at;” and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
If you purchased or otherwise acquired Papa John’s International, Inc. securities during the Class Period, you may move the Court no later than November 2, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles H. Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles H. Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
Akcie společnosti Joby Aviation za poslední měsíc klesly o 20 % na 5,14 USD; firma v tomto období nezveřejnila žádné oznámení, které by tento pokles vysvětlovalo.
Joby Aviation has shed a fifth of its value in a single month while the broader market climbed, and the reasons point to something bigger than one company's bad stretch. Here is what the numbers reveal about whether holders should…
Joby Aviation (NYSE:JOBY | JOBY Price Prediction) stock is down 20% over the past month to $5.14. This drop leaves shareholders mulling whether to stay with the electric air taxi developer.
Meanwhile, Archer Aviation (NYSE:ACHR) stock is down 16% over the past month to $4.61, representing a smaller decline than Joby stock’s. Additionally, EHang Holdings (NASDAQ:EH) stock is down 12% over the past month to $4.03, a lighter drop than Joby’s as well.
For a broader read, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is up 2% over the past month to $777.80. The ARK Autonomous Technology & Robotics ETF (BATS:ARKQ), which holds both Joby and Archer Aviation, is down 0.2% over the same stretch to $121.80. That split frames the question for Joby holders: the selling has concentrated in one narrow industry group while the broad market climbed.
Air Taxi Names Fell Together
All three electric air taxi stocks fell over the past month while the S&P 500 fund rose, a pattern that points to selling across one group of companies. Joby has issued no announcement in the past month that explains the decline. Its most recent major update came on its August 5 call covering the second quarter of 2026, when CFO Rodrigo Brumana reported revenue of $39 million, drawn primarily from the Blade passenger helicopter business, as the company raised its full-year sales guidance.
On the same call, Brumana said Joby ended the quarter with approximately $2.3 billion in cash, cash equivalents and short-term investments. Brumana also reported a net loss of $245 million under generally accepted accounting principles and guided to second-half cash use of $385 million to $415 million. Those results precede the past-month window, so they frame Joby’s finances without accounting for the recent selling.
What the Peer Group Says About Joby
Joby is building an electric aircraft that takes off vertically, and it needs regulatory certification before it can carry paying passengers, but until then, almost all of Joby’s current revenue comes from Blade, the conventional helicopter business it acquired.
Skeptics start with the spending guidance, which points to heavy outlays through the rest of the year while the revenue that matters still sits ahead of certification. A company funding a long timeline is exposed every time risk appetite contracts. JoeBen Bevirt, Joby’s founder and chief executive at the time of the call, acknowledged the execution challenge, stating, “As we’ve said before, manufacturing is hard.”
Supporters of Joby stock point to a cash position that’s large relative to the company’s size, and they also note that the helicopter business already produces revenue while the aircraft moves through certification. Brumana added that Joby can “stage a portion of that spend to match our progress, keeping our usual capital discipline.”
What to Watch Next
Joby’s next test is whether certification milestones arrive on the timetable management has described. Traders may want to check for whether second-half cash use lands inside the guided range. Either result could reset how the market prices Joby’s long timeline.
A stock tied to a certification calendar can swing sharply in both directions, and Joby’s past month shows the downside of that profile in plain terms. It makes sense to keep one’s positions modest enough that further volatility in the air taxi group wouldn’t force a rushed decision (we wrote a free guide on sizing speculative positions with rules that keep them from hurting, here: Small Stakes, Big Swings).
Contact [email protected] for any questions or corrections.
Proven Financial and Operating Leader to Help Advance Mueller’s Strategy and Next Phase of Growth
Melissa Rasmussen to Support a Smooth Transition Through Year-End
ATLANTA, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Mueller Water Products, Inc. (NYSE: MWA), a leading manufacturer and marketer of products and solutions used in the transmission, distribution and measurement of water in North America, today announced a planned transition of its Chief Financial Officer with the appointment of Michael Morgan as Executive Vice President, Finance, effective October 28, 2026. Mr. Morgan will assume the role of Executive Vice President and Chief Financial Officer on or about November 19, 2026, following the filing of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2026 (the "Annual Report"). Melissa Rasmussen will continue to serve as Chief Financial Officer through the filing of the Annual Report and will remain with Mueller in an advisory role through December 31, 2026, to support a smooth transition.
Mr. Morgan is an accomplished financial and operating leader with more than 30 years of experience. He currently serves as Chief Financial Officer of Indicor, a diversified industrial company, where he is accountable for enterprise finance strategy, capital allocation and portfolio optimization. Prior to Indicor, Mr. Morgan spent a decade at Labcorp, where he served as Senior Vice President of Enterprise Finance and Chief Financial Officer of both the company’s Biopharma Laboratory Services and Diagnostics segments. In those roles, he led financial strategy, enterprise FP&A and acquisition integration. Earlier, Mr. Morgan held finance, operational and commercial leadership roles at The Timken Company, including as Vice President and Group Controller, as well as finance leadership and investor relations roles at PerkinElmer. Mr. Morgan earned a Master of Business Administration, with concentrations in Finance and Accounting, from the University of Notre Dame and a Bachelor of Arts in Economics and Political Science from Miami University.
“Mike is a proven industrial finance leader with an extensive track record working with management teams and boards to improve performance and drive profitable growth,” said Paul McAndrew, President and Chief Executive Officer of Mueller Water Products. “His operational background and experience in financial strategy will strengthen how we plan, forecast and execute across the business. Mike will be an important partner in advancing the Mueller Operating System and translating operational improvements into sustained value for customers, employees and shareholders.”
“I am excited to join Mueller, a company whose products play an essential part in delivering safe, reliable water to communities across North America,” said Mr. Morgan. “I look forward to partnering with Paul and the leadership team to strengthen execution, support disciplined investment in the business and advance Mueller’s strategy for profitable growth and long-term value creation.”
Mr. McAndrew continued, “On behalf of the Board and the entire Mueller team, I want to thank Melissa for her contributions and commitment to Mueller. She has played an important role in strengthening our finance organization and supporting Mueller’s priorities, and we appreciate her commitment to supporting an orderly transition. We wish her continued success.”
Ms. Rasmussen’s transition and separation are not the result of any disagreement with the Company on any matter relating to the Company’s financial statements, internal control over financial reporting, operations, policies, or practices.
Forward-Looking Statements
This press release contains certain statements that may be deemed “forward-looking statements” within the meaning of the federal securities laws. These include statements regarding the Company’s strategy, execution, operational improvements, growth and long-term value creation. Forward-looking statements are based on certain assumptions and assessments made by the Company in light of the Company’s experience and perception of historical trends, current conditions, and expected future developments. Actual results and the timing of events may differ materially from those contemplated by the forward-looking statements due to a number of factors. These factors include the Company’s ability to complete an orderly leadership transition; the Company’s ability to attract and retain key personnel; the Company’s ability to execute its strategy, including the Mueller Operating System and related operational improvements, and the other factors described in the section entitled “RISK FACTORS” in Item 1A of the Company’s most recent Annual Report on Form 10-K and in later filings on Form 10-Q, as applicable. Forward-looking statements do not guarantee future performance and are only as of the date they are made. The Company undertakes no duty to update its forward-looking statements except as required by law.
About Mueller Water Products, Inc.
Mueller Water Products, Inc. is a leading manufacturer and marketer of products and solutions used in the transmission, distribution and measurement of water in North America. Our broad portfolio includes engineered valves, fire hydrants, pipe connection and repair products, metering products, leak detection, pipe condition assessment, pressure management products, and software that provides critical water system data. We help municipalities increase operational efficiencies, improve customer service and prioritize capital spending, demonstrating why Mueller Water Products is Where Intelligence Meets Infrastructure®. Visit us at www.muellerwaterproducts.com.
Mueller refers to one or more of Mueller Water Products, Inc. (MWP), a Delaware corporation, and its subsidiaries. MWP and each of its subsidiaries are legally separate and independent entities when providing products and services. MWP does not provide products or services to third parties. MWP and each of its subsidiaries are liable only for their own acts and omissions and not those of each other.
Společnost Cytokinetics uvedla, že aficamten v 36. týdnu ve srovnání s placebem významně zlepšil globální výkonnost při zátěži měřenou skóre BEAP-RS u pacientů s neobstrukční hypertrofickou kardiomyopatií.
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, AZ.
“These additional analyses from ACACIA-HCM add to the body of evidence supporting the overall benefit-risk profile of aficamten in patients with nHCM,” said Stephen Heitner, M.D., Cytokinetics’ Chief Medical Officer. “The current CPET analysis demonstrates significant improvement in a clinically relevant and novel metric of global exercise performance, while additional data provide insights into dose titration and reinforce our confidence in the safety and treatment effect of aficamten in nHCM. We plan to submit a supplemental New Drug Application to the FDA this quarter.”
ACACIA-HCM: Effect of Aficamten on Comprehensive Exercise Performance
Data from a prespecified analysis of comprehensive exercise performance from ACACIA-HCM were presented in a Late Breaking Clinical Trial Presentation. This analysis examined the effect of aficamten on multiple exercise parameters using the novel 2026 Boston Exercise Aggregate Physiologic Response Score (BEAP-RS). The score captures outputs from five individual domains, ranging from submaximal exercise through to recovery, and generates a composite of global exercise performance. At 36 weeks, treatment with aficamten significantly improved BEAP-RS compared to placebo (p<0.001), with improvements in individual exercise and recovery measures across all five domains. Improvement in BEAP-RS correlated significantly with improvements in health status measured by both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) (p = 0.001) and New York Heart Association (NYHA) Functional Class (p = 0.001), as well as the cardiac biomarker NT-proBNP (p<0.001). This analysis provides a greater understanding of the complete impact of aficamten on exercise capacity in patients with non-obstructive HCM (nHCM).
ACACIA-HCM: Global Efficacy Responder Analysis
Data from a responder analysis of ACACIA-HCM evaluating the global efficacy of aficamten in patients with symptomatic nHCM were presented in a Late Breaking Clinical Trial Presentation. The results were published in Circulation in August 2026.1 The analysis assessed clinical improvements across five key domains. At 36 weeks, a greater proportion of patients treated with aficamten demonstrated a clinically meaningful response compared to placebo in all five domains, with statistically significant improvements in four domains: relief of limiting symptoms, decrease in left atrial volume index (LAVI), increase in septal e’ velocity and ≥50% reduction in NT-proBNP (all p<0.05). An increase in peak VO2 of at least 0.5 mL/kg/min was observed in 45% of patients on aficamten compared to 37% on placebo (p=0.1). Overall, 53% of patients on aficamten demonstrated a clinical response in three or more domains compared to only 13% of patients on placebo (p<0.001). These data place the primary results into clinical context and underscore the opportunity to impact several aspects of disease burden by addressing the underlying pathobiology in patients living with symptomatic nHCM.
ACACIA-HCM: Dose Titration and Safety
Data related to dose titration and the safety profile of aficamten in ACACIA-HCM were also presented. At the end of the titration period, 80.7% of patients were on 15 or 20 mg. Dose titration led to predictable, dose-proportional changes in plasma concentration of aficamten and reductions in left ventricular ejection fraction (LVEF), which then remained stable from Week 8 through Week 36. LVEF <50% occurred in 27 (10.5%) patients taking aficamten and in two (0.8%) patients taking placebo. The only patient characteristics associated with LVEF <50% were lower baseline LVEF and permanent atrial fibrillation. As previously reported, two participants on aficamten experienced a serious adverse event (SAE) of heart failure associated with LVEF <50%. Ten additional patients on aficamten had SAEs of heart failure not associated with LVEF <50%, for a total of 12 patients (4.7%) compared to three patients (1.2%) on placebo. All heart failure events in patients treated with aficamten occurred during dose titration or prior to Week 12, often following a precipitating event such as rapid atrial fibrillation or infection, and responded to typical medical therapy such as diuretics. Overall, these data suggest that, in ACACIA-HCM, titration of aficamten to the maximum tolerated dose based on LVEF alone was generally well tolerated in the great majority of patients with nHCM.
About MYQORZO® (aficamten)
MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union and United Kingdom for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction. MYQORZO was engineered to achieve a predictable exposure response, rapid onset of action and reversibility.2
Aficamten was also evaluated in a pivotal Phase 3 clinical trial, ACACIA-HCM, in patients with non-obstructive HCM (nHCM), which met both dual primary endpoints, demonstrating statistically significant improvements in both dual primary endpoints of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and maximal exercise performance (pVO2). Statistically significant improvements compared to placebo were also observed in key secondary endpoints. There were no new safety signals identified. Left ventricular ejection fraction (LVEF) <50% occurred in 10% of participants taking aficamten and in 1% of participants taking placebo. Overall, 12 (4.7 %) patients on aficamten had serious adverse events of heart failure compared to three patients (1.2%) on placebo.
Aficamten is also under clinical investigation in CEDAR-HCM in a pediatric population with oHCM. Safety and efficacy of aficamten have not been established in a pediatric patient population. In addition, aficamten is being studied in FOREST-HCM, an open-label extension clinical study.
INDICATION
MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF HEART FAILUREMYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF <55% is not recommended. Decrease the dose of MYQORZO if LVEF is <50% and ≥40%. Interrupt the dose of MYQORZO if LVEF <40% or if the patient experiences heart failure symptoms or worsening clinical status due to systolic dysfunction.
Because of the risk of heart failure due to systolic dysfunction, MYQORZO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS Program.
CONTRAINDICATIONS
MYQORZO is contraindicated with concomitant use of rifampin.
WARNINGS AND PRECAUTIONS
Heart Failure
MYQORZO reduces cardiac contractility, which can reduce LVEF and cause heart failure.
Patients who experience a serious intercurrent illness (eg, serious infection) or arrhythmia (eg, new or uncontrolled atrial fibrillation) may be at greater risk of developing systolic dysfunction and heart failure.
Assess patients’ clinical status and LVEF prior to and during treatment and adjust the MYQORZO dose accordingly. New or worsening arrhythmia, dyspnea, chest pain, fatigue, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide may be signs and symptoms of heart failure.
Initiation of MYQORZO in patients with LVEF <55% is not recommended.
MYQORZO REMS Program
MYQORZO is available only through a restricted program called the MYQORZO REMS Program, because of the risk of heart failure due to systolic dysfunction.
Notable requirements of the MYQORZO REMS Program include:
Prescribers must be certified by enrolling in the MYQORZO REMS ProgramPatients must enroll in the MYQORZO REMS Program and comply with ongoing monitoring requirementsPharmacies must be certified by enrolling in the MYQORZO REMS Program and must only dispense to patients who are authorized to receive MYQORZOWholesalers and distributors must only distribute to certified pharmacies Further information is available at www.MYQORZOREMS.com, or at 1-844-285-7367.
Cytochrome P450 Interactions Leading to Heart Failure or Loss of Effectiveness
MYQORZO is metabolized primarily by CYP2C9, and to a lesser extent by CYP3A, CYP2D6, and CYP2C19 enzymes. Initiation of medications that inhibit multiple P450 pathways of MYQORZO elimination (eg, fluconazole, voriconazole, or fluvoxamine) or strong CYP2C9 inhibitors, and discontinuation of moderate-to-strong CYP3A inducers may lead to increased blood concentrations of aficamten and increase the risk of heart failure due to systolic dysfunction. Conversely, initiation of medications that induce P450 pathways of MYQORZO (eg, rifampin, moderate-to-strong CYP3A inducers) may lead to decreased blood concentrations of aficamten and potential loss of effectiveness. Assess LVEF 2 to 8 weeks after initiation of such inhibitors or after discontinuation of such inducers and adjust the dose of MYQORZO accordingly.
Advise patients of the potential for drug interactions. Advise patients to inform their healthcare provider of all concomitant medications prior to and during MYQORZO treatment.
ADVERSE REACTIONS
Hypertension (8% vs 2%) was the only adverse reaction occurring in >5% of patients and more commonly on MYQORZO than on placebo in the pivotal trial.
INDICATIONS AND USAGE
MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
Please see full Prescribing Information approved in the U.S., including Boxed WARNING.
Please see full Summary of Product Characteristics approved in the European Union.
About Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle becomes abnormally thick. HCM can be obstructive, when thickened muscle blocks blood flow, or non-obstructive, when blood flow is not blocked but heart function is still affected. In obstructive HCM, the thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller, stiffer and less able to relax and fill with blood. Ultimately, HCM limits the heart’s pumping function, leading to reduced exercise capacity and a variety of symptoms.
HCM is the most common monogenic inherited cardiovascular disorder, affecting approximately 1 out of 350 individuals worldwide.3
Approximately half of patients with HCM have obstructive HCM (oHCM) and half have non-obstructive HCM (nHCM).4
People with HCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease.5 People with HCM are at risk for potentially fatal ventricular arrhythmias and it is one of the leading causes of sudden cardiac death in younger people or athletes.6 A subset of patients with HCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union and United Kingdom for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to our ability to obtain regulatory approval for aficamten in nonobstructive hypertrophic cardiomyopathy in any jurisdiction by any particular date, if ever, the number of patients comprising the eligible treatment population for aficamten, or market acceptance of aficamten for the treatment of nonobstructive hypertrophic cardiomyopathy. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union and the United Kingdom.
References
Maron MS, et al. Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM. Circ. 2026Maron, MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. doi:10.1056/NEJMoa2401424Tsenov et al. Healthcare access, symptom burden, and psychological impact in hypertrophic cardiomyopathy: a multinational patient-driven survey. Int J Cardiol Cardiovasc Risk Prev2025 Aug 4;27:200485. doi: 10.1016/j.ijcrp.2025.200485Butzner M, et al. Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023. JACC Adv. 2026;5(2):102552. doi:10.1016/j.jacadv.2025.102552Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260.Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
F&G Annuities & Life, Inc. (NYSE:FG – Get Free Report) hit a new 52-week low during trading on Monday. The stock traded as low as $19.11 and last traded at $19.0470, with a volume of 41,345 shares trading hands. The stock had previously closed at $19.26.
Wall Street Analyst Weigh In A number of research firms recently commented on FG. Barclays decreased their price objective on shares of F&G Annuities & Life from $27.00 to $24.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 7th. Wall Street Zen cut shares of F&G Annuities & Life from a “buy” rating to a “hold” rating in a report on Sunday, July 5th. Weiss Ratings downgraded shares of F&G Annuities & Life from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday. Finally, Zacks Research downgraded shares of F&G Annuities & Life from a “hold” rating to a “strong sell” rating in a research report on Thursday, September 3rd. Two equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $24.00.
View Our Latest Report on FG
F&G Annuities & Life Stock Down 1.5% The firm has a market capitalization of $2.48 billion, a PE ratio of 6.47 and a beta of 1.19. The firm’s 50-day moving average is $23.93 and its 200 day moving average is $26.38. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.30 and a current ratio of 0.30. F&G Annuities & Life (NYSE:FG – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.65 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.13). F&G Annuities & Life had a return on equity of 10.28% and a net margin of 6.89%. The business had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.49 billion. As a group, research analysts forecast that F&G Annuities & Life, Inc. will post 2.93 earnings per share for the current fiscal year.
F&G Annuities & Life Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 16th were given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 5.3%. The ex-dividend date was Wednesday, September 16th. F&G Annuities & Life’s payout ratio is currently 34.13%.
Institutional Investors Weigh In On F&G Annuities & Life A number of large investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP lifted its holdings in F&G Annuities & Life by 32.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,480,179 shares of the company’s stock valued at $37,475,000 after purchasing an additional 358,616 shares in the last quarter. Stephens Inc. AR raised its position in shares of F&G Annuities & Life by 2,230.2% in the first quarter. Stephens Inc. AR now owns 266,175 shares of the company’s stock valued at $6,740,000 after buying an additional 254,752 shares during the last quarter. SEB Asset Management AB acquired a new position in F&G Annuities & Life in the 1st quarter valued at $5,810,000. Edgestream Partners L.P. lifted its stake in shares of F&G Annuities & Life by 29.1% during the 1st quarter. Edgestream Partners L.P. now owns 191,759 shares of the company’s stock worth $4,855,000 after purchasing an additional 43,264 shares during the period. Finally, Hsbc Holdings PLC purchased a new position in shares of F&G Annuities & Life during the 4th quarter worth $989,000. Institutional investors and hedge funds own 95.86% of the company’s stock.
F&G Annuities & Life Company Profile (Get Free Report)
F&G Annuities & Life, Inc (NYSE: FG) is a life insurance and annuity company that provides retirement and protection solutions to individuals and institutions. The company operates through insurance subsidiaries and focuses on helping customers accumulate, preserve and transfer wealth.
F&G’s product portfolio includes fixed indexed annuities, fixed-rate annuities and other retirement income products, as well as life insurance offerings such as indexed universal life and other protection-oriented policies.
Recommended Stories Five stocks we like better than F&G Annuities & Life China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit 3 REITs That May Win in a Higher Interest Rate Environment Broadcom’s Anthropic Bet Gets Bigger as $60 Billion Financing Raises the Stakes Insider Buying Signals Opportunity in H.B. Fuller, FocalTherics, Cardinal Receive News & Ratings for F&G Annuities & Life Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F&G Annuities & Life and related companies with MarketBeat.com's FREE daily email newsletter.
Tržby Jimmy Choo v 1. čtvrtletí fiskálního roku 2027 vzrostly meziročně o 10,5 % na 179 mil. USD, zatímco provozní zisk stoupl na 13 mil. USD ze 4 mil. USD.
Key Takeaways Jimmy Choo's Q1 revenues rose 10.5% to $179 million, led by 26% growth in the Americas.Strong accessories demand and targeted campaigns boosted customer engagement, with VIP sales climbing 40%.CPRI's Jimmy Choo operating margin rose 480 basis points to 7.3%, while operating income reached $13 million.
Capri Holdings Limited (CPRI - Free Report) is building momentum at Jimmy Choo through product innovation, targeted marketing and stronger customer engagement. Expanding accessories and casual footwear offerings are broadening customer appeal, while an enhanced pricing architecture is attracting younger shoppers without compromising luxury positioning. These initiatives are building the brand’s foundation for sustainable growth.
In first-quarter fiscal 2027, Jimmy Choo’s revenues increased 10.5% year over year to $179 million, exceeding management’s expectations. Constant-currency growth was 9.3%. Revenues rose 26% in the Americas, 5% in Europe, the Middle East, and Africa (EMEA) and 3% in Asia. Retail and wholesale both recorded low-double-digit growth, with North American department stores delivering double-digit point-of-sale increases.
Marketing efforts reinforced consumer connections. The Natural Reflection campaign featured the Glace Mule, Jelly Drop sandal and Cinch bag. An influencer trip to Nice brought together 16 creators with more than 36 million combined followers, generating nearly 50 million impressions. Curated Bon Bon client events drove a 40% increase in very important client sales, while Jimmy Choo’s global consumer database expanded 7% year over year.
Accessories sales grew at a double-digit pace, with Bon Bon and Cinch performing strongly and Bar and Curve styles broadening brand reach. Management also reported encouraging dress and casual footwear performance, highlighting the Faiz lace pump, Margot Flat and Sunny sneaker. Campaigns featuring Wang Yibo and Bai Lu strengthened visibility in Asia, complementing efforts to attract new customers.
Higher revenues improved expense leverage, lifting operating income to $13 million from $4 million and expanding the operating margin by 480 basis points to 7.3%. However, channel mix primarily drove a 170-basis-point decline in gross margin to 68.7%. Capri’s adjusted fiscal 2027 outlook anticipates approximately $635 million in Jimmy Choo revenues and a low-single-digit operating margin. Continued product innovation and deeper consumer engagement remain central to turning the brand’s regional momentum into sustained profitable growth.
CPRI’s Price Performance, Valuation & EstimatesShares of Capri Holdings have lost 25.5% over the past six months compared with the industry’s 8% decline.
Image Source: Zacks Investment Research
From a valuation standpoint, CPRI trades at a forward price-to-earnings ratio of 6.38, below the industry’s average of 12.96. It has a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Capri Holdings’ fiscal 2027 earnings implies year-over-year growth of 40.7%, whereas the same for fiscal 2028 indicates an uptick of 21%. Earnings estimates for fiscal 2027 and 2028 have remained unchanged over the past 60 days.
Image Source: Zacks Investment Research
CPRI’s Zacks Rank & Key PicksCapri Holdings currently carries a Zacks Rank #3 (Hold).
Genesco Inc. (GCO - Free Report) is a Nashville-based specialty retailer and branded company. It sells footwear and accessories through retail stores. The company sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Genesco’s current fiscal-year earnings indicates 62.1% growth from the year-ago actual. GCO delivered a trailing four-quarter average earnings surprise of 11.2%.
Designer Brands Inc. (DBI - Free Report) designs, produces and retails footwear and accessories. It offers shoes, boots, sandals, sneakers, socks, handbags and accessories. It currently carries a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for Designer Brands’ current fiscal-year earnings and sales suggests growth of 225% and 0.6%, respectively, from the year-ago actuals. DBI delivered a trailing four-quarter average earnings surprise of 108.1%.
G-III Apparel Group, Ltd. (GIII - Free Report) designs, sources, distributes and markets a broad range of apparel and accessories under owned, licensed and private-label brands. The company also holds a Zacks Rank of 2 at present.
The Zacks Consensus Estimate for G-III Apparel’s current fiscal-year earnings and sales suggests decline of 13.8% and 8.4%, respectively, from the year-ago actuals. GIII delivered a trailing four-quarter average earnings surprise of 1.4%.
SummaryIntuitive, AI-native design workflows have driven robust adoption across Figma's growing seat-based subscription and AI credit consumption at >80% of $10K+ ARR customers.New launches remain in beta mode and, therefore, are yet to consume paid AI credits, with the eventual general launch likely to be top/bottom-line accretive.Premium valuation persists at EV/Sales of 7.12x, but FIG’s Rule of 67.2% outperformance (revenue growth/FCF margin) and net cash of $1.66B underpin long-term resilience.Risks include insider selling, a hefty SBC to revenue ratio of 44.9%, and equity dilution, but the trading floor at the $16s and resistance at the $27s offers a swing trade potential.FIG remains a contrarian Buy, supported by robust SaaS adoption, resilient high-value customer growth, and strong net retention metrics despite sector-wide SaaSpocalypse fears. Mininyx Doodle/iStock via Getty Images
Figma (FIG) has proven their ability to strategically integrate new acquisitions/AI-native functionalities into the existing creative workflows, with it driving the robust adoption and top-line growth prospects despite the ongoing SaaSpocalypse fears.
Given the
16.29K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Akcie SanDisk v pondělí klesly o 5,7 %, přestože Goldman Sachs vidí příležitost v pamětech HBF pro AI; její ziskovost však závisí na cenách, výrobní výtěžnosti a schválení ze strany zákazníků.
Sandisk, the flash-memory supplier SNDK , faces a profitability test behind its AI-memory opportunity, with shares down 5.7% to $1,491.35 at 12:41 p.m. ET on Monday. Investing.com's October 12 report outlined Goldman Sachs' bullish case for high-bandwidth flash, or HBF. The opportunity is clear. The harder question is how much profit Sandisk can squeeze from the factory capacity needed to deliver it.
Sandisk and SK hynix released an Open Compute Project technical specification on August 3, with Google and Tenstorrent contributing to validation and standardization. The framework supports AI systems that place more memory near computing cores and allows HBF to work alongside high-bandwidth memory. That gives designers a foundation to build on. It does not guarantee orders. The GF Score of 45/100 shows strong growth and financial-strength readings alongside weaker profitability, suggesting investors should look beyond the growth story.
According to Investing.com, Goldman's optimistic scenario puts HBF at 9% of global NAND wafer capacity but just 4% of bit shipments by late 2028. Those shares imply a 2.25-to-one ratio of capacity share to shipment share. My take: heavier wafer consumption could tighten supply and support pricing, but it also raises the bar for returns. Sandisk still needs customer approvals, reliable manufacturing yields and prices that reward the capacity consumed. Technical progress opens the door. Profitable orders make the investment case.
Pojistný trh poskytuje pro jeden start krytí maximálně kolem 650 mil. USD, zatímco výstavba stanice Starlab společnosti Voyager Technologies má stát 2,8 až 3,3 mld. USD.
SpaceX (NASDAQ:SPCX) has a rocket big enough to carry a space station. The insurance market isn’t built to cover one.
Andrew Bonwick, VP of Product Development at Relm, told Benzinga that coverage for one launch tops out far below the value of a full Starship load.
“As things stand, the maximum insurance capacity in the market today is around $650 million for any one launch,” Bonwick said. “A 100T payload will be much more valuable than this.”
SPCX stock is moving. See the chart and price action here. A Station Worth BillionsVoyager Technologies Inc. (NYSE:VOYG) is the clearest test case. Its Starlab station is designed to launch on a single Starship flight. Voyager estimates Starlab will cost $2.8 billion to $3.3 billion to design, build and launch.
Its annual report expects a 2029 launch.
At that cost, $650 million would cover only about 20% to 23% of the station. The filing itself warns that “the insurance market for the launch and operation of a non-governmentally owned, crewed space station does not currently exist.”
Bonwick says outside capital could help. “For much bigger payloads, such as one Starlab worth several billion dollars, alternative markets, insurance-linked securities and derivatives could be used to top up coverage,” he said.
Read Next
A Small MarketSpecialty insurance provider Gallagher Specialty puts the market’s competitive capacity at about $300 million in 2026. A single loss can swing results.
The total loss of SpainSat NG-2, insured for more than $400 million, pushed the market’s 2025 loss ratio from about 15% to about 75%, Gallagher said.
Starship Has to Earn Lower RatesStarship reached orbit for the first time in September, even with an upper-stage engine shutting down during ascent.
SpaceX self-insures Starlink, so the 26 satellites it carried were almost certainly not covered on the open market, Insurance Business reported.
Bonwick said Starship will be “looked on favorably because it is SpaceX, but it is a completely different vehicle in terms of fuel, engines and size.” He expects “initial insurance prices will be high, although they will come down quickly if Starship proves to be reliable.”
Voyager shares trade near $27.28, about 45% below their May 28 close of $51.77. The stock fell 16% on Sept. 23 after Voyager launched what became a $402.5 million convertible-note sale.
SPCX Stock Price Activity: SpaceX stock was up 0.63% at $163.59 at the time of publication Monday, according to data from Benzinga Pro.
, /PRNewswire/ -- Meta Platforms, Inc. (NASDAQ: META) announced today that the company's third quarter 2026 financial results will be released after market close on Wednesday, October 21st, 2026.
Meta will host a conference call to discuss its results at 1:30 p.m. PT / 4:30 p.m. ET the same day. The live webcast of the call can be accessed at the Meta Investor Relations website at investor.atmeta.com, along with the company's earnings press release, financial tables, and slide presentation.
Following the call, a replay will be available at the same website. Transcripts of conference calls with publishing equity research analysts held on October 21st, 2026 will also be posted to the investor.atmeta.com website.
Disclosure Information
Meta uses the investor.atmeta.com and meta.com/news websites as well as Mark Zuckerberg's Facebook profile (facebook.com/zuck), Instagram account (instagram.com/zuck) and Threads profile (threads.net/zuck) as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
About Meta
Meta is building the future of human connection, powered by artificial intelligence and immersive technologies. When Facebook launched in 2004, it changed the way people connect. Apps like Messenger, Instagram, and WhatsApp further empowered billions around the world. Now, Meta is moving toward building experiences that foster deeper connections and unlock new possibilities.
Contacts
Investors:
Rob Bevegni
[email protected] / investor.atmeta.com
Amazon deaktivoval prodejní účet společnosti Bed Scrunchie těsně před svátky v roce 2024. Její tržby v roce 2024 dosáhly přibližně 4,5 milionu USD. Amazon však stále představuje odhadem 70–80 % prodejů značky.
You're currently following this topic! Click to unsubscribe from email alerts.
This entrepreneur says Amazon nearly destroyed his business. He still shops on it every week. 'It's crazy.' By and Jessica Orwig You're currently following this author! Click to unsubscribe from email alerts.
Jack Nekhala has every reason to stop shopping on Amazon.
His company, Bed Scrunchie, generated about $4.5 million in 2024 and was on track for more, Nekhala said. However, Amazon deactivated its seller account just before the holidays that year, cutting off its biggest sales channel.
"Once the collapse happened through Amazon, it basically collapsed the entire business," Nekhala told Business Insider for our So Expensive video series.
That makes his next admission harder to say.
"I still shop on Amazon," Nekhala said. "I have a daughter. She needs bikes. She needs a scooter, she needs all sorts, she needs different things. And that's the place we go to."
He said he shops on Amazon two to three times a week and sometimes has several orders in a single day.
The habit bothers him more than he can explain, he said. "Continuing to shop there feels like being forced to sit down to dinner with the institution that upended your life."
Founders of the Bed Scrunchie: Jack Nekhala (left) and Michael Nusinkis (right). Courtesy of Jack The account shutdown, he said, left him and his business partner carrying debt and trying to rebuild the financial security they had spent nearly 20 years creating for their young families. "My life has not been the same," he said.
For Nekhala, his Amazon shopping habit reflects how deeply the online marketplace has become embedded in everyday life. In a recent survey of shoppers across the US and Europe, 75% of consumers said they buy from Amazon at least once a month.
"I do not shop there because I have forgiven what happened. I shop there because Amazon has made itself so convenient and embedded in everyday life that even people who feel harmed by it continue to depend on it," Nekhala said.
"It's crazy," he added of his own shopping habits. "It's really incredible what they've accomplished."
Amazon became the default
Business Insider The appeal of Amazon isn't just price. It's the convenience, Nekhala said.
Amazon already has his payment information, shipping addresses, and purchase history. Adding one more item to an order is often easier than creating an account somewhere else, he said.
"They remove all the friction," Michael Nusinkis, Nekhala's business partner, said.
"I think you just have this muscle memory. I need to buy something — Amazon," Nusinkis added.
The founders saw that same behavior from their own customers.
Before Amazon deactivated their seller account, the pair aired a national television infomercial directing viewers to a website where they could buy the Bed Scrunchie directly for $39.99.
On Amazon, the product sold for $44.95. And they said Amazon sales of the item consistently spiked whenever the infomercial aired.
"All advertising roads lead back to Amazon," Nekhala said.
Nekhala said customers would likely discover the product on television or the company's website, then go to Amazon to compare options, read reviews, and buy it—even at a higher price.
Surveys suggest up to three-quarters of Amazon shoppers start their product searches there.
Even after losing their account, the business couldn't leave Amazon
The bed scrunchie is designed to prevent sheets and mattress toppers from sliding off a mattress. Business Insider After months of disputes with Amazon, including allegations that the company had infringed its own patent and violated Amazon's review policies, Nekhala and Nusinkis lost their seller account. The founders dispute both allegations.
They now sell Bed Scrunchie to a third-party distributor, which keeps it available on Amazon for $49.99. Nekhala estimates that Amazon still accounts for 70% to 80% of the company's sales.
That means shoppers may see the Bed Scrunchie name on Amazon without realizing they are buying from a reseller—not the small business that created it, he said.
"Amazon shut out the people who invented and built the product, yet the product remains on its platform at a higher price," Nekhala added. "That contradiction is what makes continuing to shop there so painful."
Nekhala said the company would rather sell the product for less on its own website. But he believes Amazon's pricing policies make that difficult: Listing it more cheaply elsewhere, he said, could mean the product loses visibility or prominent placement on Amazon.
As a result, he said, sellers keep prices in line across retailers, even when it means customers pay more.
That's one of the practices at the center of a lawsuit California's attorney general filed against Amazon, alleging it pressures brands and third-party sellers to raise prices at competing retailers so Amazon isn't undercut.
In a statement to Business Insider, Amazon says its goal is to protect customers from overpaying and maintain trust in its marketplace by comparing prices with other reputable retailers. If a product is listed for less elsewhere, Amazon says it may choose not to prominently feature that offer, though it remains available for purchase. Amazon also argues California's case relies on a handful of emails taken out of context and says the challenged practices are common retail negotiations designed to deliver "low prices, vast selection, and unmatched convenience" for customers.
Read next
A.C. Fowler You're currently following this author! Click to unsubscribe from email alerts.
A. C. is a Deputy Executive Producer for Business Insider's video team, developing strategy and overseeing production on several shows. Fowler was nominated for a 2026 News and Documentary Emmy Award for his work on Why concert tickets are so expensive — and who's to blame, and won a NATJA award for coverage of the plight of Sherpas on Mount Everest. He also published "Him," a first-of-its-kind documentary project intimately following the life of an Ohio man in a 3-year-long relationship with his AI chatbot. If you have story ideas, you can reach A. C. at [email protected] joining Business Insider he did his undergraduate studies in journalism and political science at Ohio University and later attended the graduate journalism program at Northwestern University. Between undergraduate and graduate school he worked in the Digital Strategies field in Ljubljana, Slovenia.
Jessica Orwig You're currently following this author! Click to unsubscribe from email alerts.
Jessica Orwig is a senior editor at Business Insider, where she collaborates with reporters, editors, and producers across teams to shape, write, edit, and publish stories that connect with a global audience. While her roots are in science and technology journalism, her work today spans business, careers, culture, and the big ideas shaping the future.She earned her Master’s in Science & Technology Journalism from Texas A&M University and holds a Bachelor’s in Astronomy & Physics from The Ohio State University. Throughout her career, she’s helped lead coverage on everything from space exploration and climate change to innovation, the future of work, and evolving cultural trends.Career HighlightsLed coverage on scientific milestones, including:
Blue Origin's inaugural New Glenn launchIntuitive Machine's groundbreaking moon landing for the USSpaceX’s Polaris Dawn historic spaceflight NASA’s Parker Solar Probe Historic FlybyJapan’s SLIM lunar landingThe first image of a black holeIndia’s historic Moon landingSpaceX’s inaugural Starship-Super Heavy launchDiscovery of gravitational wavesNASA’s Pluto flybyReported on breaking news and scientific discoveries, including:
Microplastics in the human brainPeregrine Mission One’s failed flightThe Palisades firesSpaceX Starship explosionsDark Energy Spectroscopic Instrument’s 3D map of the universe and what it revealsA local cosmic void that shouldn’t existThe Boeing Starliner missionMexico City’s water crisisEarth’s mysterious inner core behaviorPopular stories she’s edited on science and health:
What it will take to modernize the American grid and usher in the clean-energy revolutionI study toxic microplastics. Here's how I protect myself and my kids at home.A mega-earthquake could strike the Pacific Northwest any day — and we're not preparedFlying is about to become even more miserableWhy the US can’t send humans to MarsThe world's most popular banana faces extinction but scientists' new creation could help save itScientists finally think they know where the most dangerous part of this US earthquake zone is and it's bad news for WashingtonOne of Mt. Everest's deadliest passages is growing even more treacherousJupiter's moon Europa generates enough oxygen to keep a million people alive for a day, NASA saysPopular stories she’s written and/or edited on careers, culture, life, and business:
He weighed over 400 pounds as an FBI undercover agent — and it became his best disguiseA former FBI Special Agent who infiltrated the Italian Mafia, Mexican cartels, and Russian and Asian organized crime groups says he fears 1 group above the restHe was diagnosed with colon cancer at 31 in prison, and his survival odds weren't great. Now 59, he says spiraling is pointless.I stopped bartending full-time to sell ice. My company now makes nearly $3 million a year, catering to Michelin-starred restaurants in New York City.My dad ran a food cart and called it the 'worst business.' I decided to follow in his footsteps anyway.I moved from the US to Rome for a slower pace of life, but after 7 years I've realized I'll never fully adjust to some Italian waysAfter losing too many bidding wars for a home in LA, I bought a 5-bedroom house in the suburbs. I quickly realized it was a mistake.We bought our dream home in Colorado, but wildfires and home insurance trends had us selling 1.5 years laterA woman who retired early at 58 thought she was ready with over $500,000 in savings. A few years later, it was gone.I've made over $40,000 selling plush dolls I scoop from claw machines. Here's how I learned to beat the game and turn my hobby into a profitable side hustle.A 17-year-old designed a cheaper, more efficient drone. The Department of Defense just awarded him $23,000 for it.Yukon gold miners are unearthing mummified ancient creatures and truckloads of fossils from the Ice Age. Take a look.Archaeologists are finding mysterious ancient objects on Norway's melting glaciers. Take a look.I'm an American mom in Italy. When I couldn't help my daughter with her homework, I realized how isolated I felt. Amazon Entrepreneur Retail More E-Commerce Small Business Insider
Společnost Tilray ve fiskálním prvním čtvrtletí spálila 16,5 mil. USD v hotovosti oproti 1,3 mil. USD před rokem, zatímco tržby z konopí meziročně klesly o 13 % na 56,1 mil. USD.
Last week, Tilray Brands (TLRY -5.08%) reported its first-quarter numbers for fiscal 2027. While management boasted of its record-breaking numbers and diversified business, investors shouldn't buy the hype at all.
Tilray has been a bad investment for many years, and acquisitions may have boosted its revenue, but they haven't changed the story around this troubling marijuana stock. It's a bad buy, and the three numbers below from its earnings report only confirm that.
Image source: Getty Images.
Tilray's cash burn spiked to more than $16.5 millionI've written about cannabis stocks for years and know how unreliable looking at their income statements can be; they're often filled with impairment charges and valuation changes. There's a lot of noise that can make it difficult for investors to truly understand what shape the business is in. This is why I often go straight to the cash flow statement instead.
And on a cash basis, things don't look good for Tilray. Its cash burn for the period ending Aug. 31 totaled $16.5 million, which is up significantly from $1.3 million a year ago. Cash can fluctuate significantly from one period to the next. But the reality is that Tilray has often struggled to generate consistent positive cash flow from its operations. This is even before factoring in any money it uses up from investing activities, including capital expenditures.
Tilray is a cash-burning machine, and until that changes, investors should brace for and expect stock offerings, dilution, and plenty of volatility.
Its cannabis revenue fell by 13%Tilray's cannabis revenue for the period totaled $56.1 million, which was down from $64.5 million a year ago, representing a year-over-year decline of 13%. The company's top line did rise by 23%, but that was largely due to a significant spike in its beverage business, where its BrewDog acquisition padded its numbers.
Wheeling and dealing can help manufacture this type of growth, but it's organic growth that growth investors are truly craving. Simply adding more companies to the mix can certainly make the business bigger, but not necessarily better.
Investors should tread carefully with acquisition-hungry businesses such as Tilray for this very reason, because without a way to gauge how well it's growing organically, it's difficult to see just how strong a growth stock it really is.
The fact that its core cannabis business is struggling highlights precisely why Tilray would seek investments and acquisitions elsewhere: without them, its top line wouldn't look nearly as strong.
Operating expenses soared to $101.6 millionAcquisitions can bolster the top line, but they can also drastically weigh down the bottom line. That's because a company acquires the extra staff, overhead, and other costs associated with the business. So while it may get a bump up on the top line from more revenue, it will also incur significantly more expenses. It may be able to trim some costs and remove redundancies over time, but the business will no doubt be bulkier.
Tilray's operating expenses totaled $101.6 million this past quarter, which is an increase of 83% from the same period last year. That is, however, with the company getting a $15 million benefit from the change in the fair value of contingent consideration a year ago. If that's removed, then the year-over-year increase in operating expense is 44%. But that's still higher than the company's top-line growth.
With a more bloated business, Tilray's actually going in the opposite direction of its peers, Canopy Growth and Aurora Cannabis, which have been looking to get leaner. It's not a strategy I think will end up paying off for Tilray.
Premium Feature
Moneyball Superscore
38/100
Today's Change
(
-5.08
%) $
-0.18
Current Price
$
3.36
Tilray's decline isn't likely to end anytime soonDespite top-line growth, the market didn't appear impressed with Tilray's latest numbers, as the stock has fallen since it posted them. Unfortunately, I don't see a path for the stock to get out of its tailspin anytime soon. It's a stock that's full of risk and that investors are likely better off avoiding.
The S&P 500 (^GSPC -0.06%) has had a great year so far. The average annual return of the S&P 500 is about 10%, and with it sitting at about 14.5% right now, it has been a good year. There are still a few months left, so the chances of it ending up even higher are quite good.
While the S&P 500 as a whole is doing well, a few individual performers stand out. Sandisk holds the title for best-performing S&P 500 stock this year, rising about 590% in 2026. Intel is another top performer, increasing nearly 200% so far this year. There are a handful of companies that also have had strong runs, including AMD.
So, which stock will lead the S&P 500 higher next year? I think it will be a familiar face, and it won't be one of these three.
Image source: Getty Images.
Some stocks have gotten ahead of themselves With the returns some stocks are delivering this year, it's pretty easy to guess that next year may not be as kind to these stocks. Many companies have far outgrown their business results and are trading at inflated valuations, such as Intel and AMD. These two trade for 70 and 81 times forward earnings, respectively. This showcases just how expensive they are. Others, like Sandisk, operate in a cyclical market, and the stock market is wary of giving it a standard valuation due to fears of the memory chip industry seeing a cyclical downturn.
Premium Feature
Moneyball Superscore
95/100
Today's Change
(
-2.28
%) $
-13.86
Current Price
$
594.24
Regardless, there are a handful of stocks that were abandoned to pave the way for these to rise, and the most obvious one is Nvidia (NVDA -1.29%). Nvidia led the S&P 500 in performance during 2023 and 2024, and I think it has a strong shot at leading it again in 2027. Why? Its stock has been ignored compared to some of its peers.
Nvidia is dirt cheap compared to its peers It's hard to say that the largest company in the world by market cap isn't getting a fair shake, but that's exactly what's happening. As mentioned above, AMD trades at over 80 times forward earnings. Nvidia trades at 25.
AMD PE Ratio (Forward) data by YCharts
These two companies operate in the same industry (namely, graphics processing units, or GPUs), and Nvidia is growing its data center business (the segment most exposed to artificial intelligence (AI)) at a faster pace. In Q2, Nvidia's data center division grew at a 117% pace to $89 billion. AMD's data center division grew at a 107% pace to $6.7 billion. Nvidia is still winning, and there's no reason to give AMD a ridiculous premium as a result.
Another factor is that the market hasn't priced in practically any of 2027's growth into Nvidia's stock price. The S&P 500 trades for about 20 times forward earnings. The slight premium Nvidia now commands is worth it given its positioning in the AI boom and strong track record of performance. However, Nvidia is also expected to grow its revenue by 70% next year. But Nvidia's current 25 times forward earnings valuation implies that its stock will grow at a market-average pace next year (about 10%).
Premium Feature
Moneyball Superscore
97/100
Today's Change
(
-1.29
%) $
-2.96
Current Price
$
226.32
That's a major mismatch, and I think it suggests Nvidia is poised for an exceptional year and could lead the S&P 500 in performance. While there could be others that sneak up on investors and outperform Nvidia, Nvidia is one of the few companies that has given investors high visibility into its future growth. Management has undergirded nearly every step along the way, so this 70% growth could also be a major undershoot.
With Nvidia expected to grow revenue by 70% or more next year, I think it's a no-brainer buy right now.
TORRANCE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS), a leader in next-generation power semiconductors and power delivery solutions, pioneering GaN, high-voltage and ultra-high-voltage SiC, and IVR technologies, today announced its latest 24 kW, 800 V-to-12 V DC-DC power delivery board (PDB), powered by GaNFast™ technology and developed in collaboration with NVIDIA, to support the NVIDIA MGX ecosystem and advance 800 VDC power architectures for AI data centers. The new PDB is planned to be featured on NVIDIA’s AI Factory MGX Wall partner display area at OCP Global Summit 2026.
This latest 24 kW, 800 V-to-12 V PDB extends Navitas’ portfolio of 800 VDC AI data-center platforms, building on the previously announced 20 kW, 800 V-to-6 V PDB developed in collaboration with NVIDIA. These solutions advance the core strategic focus of the Navitas 2.0 transformation to accelerate the replacement of legacy silicon with next-generation GaN and SiC high-power technologies across AI infrastructure, from Grid-to-xPU.
The PDB is capable of delivering 24 kW with a target efficiency of 97% at full load and a power density exceeding 2,000 W/in³, providing power for the entire compute tray. Designed in NVIDIA’s latest 400 mm × 60 mm form factor, the PDB can be integrated onto the compute motherboard as close as possible to the xPUs, minimizing power-delivery losses and supporting high-power demands.
The single-stage architecture converts 800 VDC directly to 12 VDC, eliminating the existing 50 V-to-12 V IBC conversion stage and delivering 12 V directly to the voltage regulator module (VRM) that powers the xPU. This simplified power architecture improves system efficiency and reliability while reducing power losses, board space and overall power-delivery complexity.
The power architecture incorporates 16 × NV6034 (650 V, 18 mΩ) GaNFast™ FETs on the primary side, configured in a stacked half-bridge topology and featuring Navitas’ latest dual-cooled DFN 8 × 8 package.
“The next era of AI will be defined not only by how much compute we can create but by our ability to deliver the power needed to unleash its full potential,” said Chris Allexandre, President and CEO of Navitas. “Our collaboration with NVIDIA is breaking the AI infrastructure power wall by reimagining power delivery from 800 VDC to the GPU. This next-generation 24 kW solution demonstrates how GaNFast™ technology can eliminate power-conversion stages, increase efficiency and power density, and bring power closer to the GPU.”
Navitas’ portfolio of 800 VDC AI data-center platforms provides customers with greater flexibility to select the optimal intermediate-bus voltage and VRM architecture for their point-of-load power requirements.
The 800 V-to-12 V PDB is planned to be showcased at the NVIDIA AI Factory MGX Wall partner display area at OCP Global Summit 2026. For more information, please contact your Navitas representative or email [email protected].
About Navitas
Navitas Semiconductor (Nasdaq: NVTS) is a leader in next-generation power semiconductors and power delivery solutions, pioneering GaN, high-voltage and ultra-high-voltage SiC, and IVR technologies for AI infrastructure, including data centers and energy and grid systems, as well as additional markets such as high-performance computing and industrial electrification. Collectively, these technologies address the complete grid-to-xPU power architecture, breaking the AI infrastructure power wall and enabling higher efficiency, greater power density, and increased performance across the entire power chain. Navitas’ GaNFast™ FETs deliver industry-leading power density, efficiency, and high-speed performance, while GaNFast™ power ICs integrate GaN power, drive, control, sensing, and protection to enable faster, more efficient power conversion, leading to smaller and more reliable systems. The GeneSiC™ portfolio combines proprietary trench-assisted planar (TAP) SiC technology with leading-edge discrete packaging and SiCPAK™ power modules to deliver industry-leading efficiency, ruggedness and performance. Claros™ IVR technologies extend power delivery directly to the xPU, enabling customers to implement vertical power delivery (VPD) and embedded power delivery (EPD) architectures with high-density power conversion beneath or within millimeters of the processor, minimizing power-delivery losses and impedance while enabling ultra-fast transient response, higher efficiency and maximum power density. Navitas has over 450 patents issued or pending and is a leader in 800 VDC and the advanced AI power infrastructure ecosystem.
Navitas®, GaNFast®, GeneSiC™, Claros™, SiCPAK®, GaNSafe®, DrGaN™, and the Navitas logo are trademarks or registered trademarks of Navitas Semiconductor Limited or affiliates. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are attempts to predict or indicate future events or trends or similar statements that are not a reflection of historical fact. Forward-looking statements may be identified by the use of words such as “we expect” or “are expected to be,” “estimate,” “plan,” “project,” “forecast,” “intend,” “anticipate,” “believe,” “seek,” or other similar expressions. Forward-looking statements are made based on estimates and forecasts of financial and performance metrics, projections of market opportunity and market share and current indications of customer interest, all of which are based on various assumptions, whether or not identified in this press release. All such statements are based on current expectations of the management of Navitas and are not predictions of actual future performance. Forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions and expectations. Many actual events and circumstances that affect performance are beyond the control of Navitas and, forward-looking statements are subject to a number of uncertainties. Our businesses are subject to certain risks that could materially and adversely affect our respective business, financial condition, results of operations, or the value of our securities. For Navitas, these and other risk factors are discussed in the Risk Factors section of our most recent annual report on Form 10-K, as updated in the Risk Factors section of our most recent quarterly report on Form 10-Q, and in other documents we file with the SEC. If any of these risks, as discussed in more detail in our SEC reports, materialize or if our assumptions underlying forward-looking statements prove to be incorrect, actual results could differ materially from the results implied by these forward-looking statements.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/add83c1f-3ef4-4e7e-b06a-5c20838cf2c2
Navitas Collaborates with NVIDIA on 800 V-to-12 V Power Delivery Board for Next-Generation AI Infras... Next-generation 24 kW power delivery board converts 800 VDC directly to 12 VDC in a single stage, el...
New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing groups Results come from the first dedicated Phase 3 randomized, placebo-controlled trial in adults managing Crohn's disease with perianal fistula in more than 20 years , /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new Phase 3 data showing consistent combined fistula remission outcomes with TREMFYA® (guselkumab) across clinically important subgroups of adults with Crohn's disease with perianal fistula.1 The prespecified subgroup analyses from the FUZION study are being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and build on previously reported Week 24 results from the overall study population.
In the overall study population, 28% of patients receiving TREMFYA 100 mg q8w and 27% receiving TREMFYA 200 mg q4w achieved the composite endpoint of combined fistula remissiona at Week 24, compared with 10% receiving placebo, making TREMFYA the only IL-23 inhibitor to demonstrate efficacy in a dedicated, randomized, placebo-controlled trial in patients with Crohn's disease with perianal fistula.1
New subgroup analyses show consistent outcomes across key patient subgroups
Expanding on previously reported results in the overall population, new prespecified subgroup analyses showed greater Week 24 combined fistula remission with TREMFYA versus placebo among:1
Patients with greater luminal disease activity at baseline (CDAI ≥220): 30% and 21% with TREMFYA 100 mg SC q8w and 200 mg SC q4w, respectively, versus 0% with placebo Patients with prior biologic exposure: 21% and 29%, respectively, versus 5% with placebo Patients with proctitis at baseline: 26% and 27%, respectively, versus 12% with placebo Patients without proctitis at baseline: 29% and 27%, respectively, versus 10% with placebo Adverse events were consistent with the known safety profile of TREMFYA in Crohn's disease.1
"Perianal fistula remain one of the most debilitating manifestations of moderate to severe Crohn's disease and many patients continue to experience persistent drainage, pain and complications," said Bruce Sands, MD, MS, Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine, and Chief, Division of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Health System. "These subgroup analyses show that the outcomes observed with TREMFYA were consistent across clinically important patient populations, further strengthening the evidence supporting its use in this difficult to treat patient population."
Addressing an important need in Crohn's disease
Perianal fistula affects nearly 25% of patients with Crohn's disease and is a severe, often debilitating manifestation associated with pain, persistent drainage, recurrent abscesses and a frequent need for surgical intervention.2 3 FUZION is a dedicated randomized, placebo-controlled Phase 3 study designed to evaluate TREMFYA in adults with Crohn's disease with perianal fistula.
"Johnson & Johnson has a longstanding commitment to advancing the science of inflammatory bowel disease, including for patients living with some of its most complex manifestations," said David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head, Johnson & Johnson. "FUZION was designed to generate rigorous evidence specifically in Crohn's disease with perianal fistula, helping us deepen our understanding of how TREMFYA can address an area of unmet need."
TREMFYA is the only approved dual-acting monoclonal antibody in inflammatory bowel disease (IBD) that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23. IL-23 is a cytokine secreted by activated monocyte/macrophages and dendritic cells that is known to be a driver of immune-mediated diseases including UC. Findings are based on in vitro studies.45678
Dr. Bruce Sands is a paid consultant for Johnson & Johnson. He has not been compensated for any media work.
For a full list of all Johnson & Johnson data being presented at ACG visit: https://www.jnj.com/innovativemedicine/immunology/gastroenterology.
Editor's notes:
a. Combined fistula remission was defined as complete closure of all external fistula openings with no drainage, without development of new fistulas, and absence of underlying fluid collections on MRI.
About the FUZION study (NCT05347095)
FUZION is a randomized, placebo-controlled, double-blind, multicenter, Phase 3 study designed to evaluate the efficacy and safety of TREMFYA in adults with Crohn's disease with perianal fistula. Patients enrolled in the study had one or more active draining perianal fistulas confirmed by blinded central MRI review, CD Activity Index [CDAI] <350, and inadequate response to oral corticosteroids, azathioprine, 6-mercaptopurine, methotrexate, or up to 2 advanced therapy classes. Patients were randomized 2:2:1 to receive TREMFYA 200 mg intravenous (IV) induction at Weeks 0, 4, 8 weeks followed by TREMFYA 100 mg subcutaneous (SC) induction every 8 weeks (q8w); or TREMFYA 200 mg IV infusion in at Weeks 0, 4, 8 weeks followed by TREMFYA 200 mg SC every 4 weeks (q4w); or placebo.9
About Crohn's disease
Crohn's disease is one of the two main forms of inflammatory bowel disease, which affects an estimated three million Americans and an estimated four million people across Europe.1011 Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet, or other environmental factors.12 Symptoms of Crohn's disease can vary, but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss, and fever. Some patients may also develop fistulas, abnormal connections between the intestine and other organs or tissues, which can be associated with pain, drainage, infection, and substantial impairment in quality of life. Currently no cure is available for Crohn's disease.13
About TREMFYA (guselkumab)
Developed by Johnson & Johnson, TREMFYA is the first fully-human, dual-acting monoclonal antibody designed to neutralize inflammation at the cellular source by blocking IL-23 and binding to CD64 (a receptor on cells that produce IL-23). Findings for the dual-acting mechanism are limited to in vitro studies that demonstrate TREMFYA binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory monocyte model. The clinical significance of this finding is not known.
TREMFYA is a prescription medicine approved in the U.S. to treat:
adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light). adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with active psoriatic arthritis. adults with moderately to severely active ulcerative colitis. adults with moderately to severely active Crohn's disease. TREMFYA is approved in Europe, Canada, Japan, and a number of other countries for the treatment of adults with moderate-to-severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate-to-severe Crohn's disease and adults with moderate-to-severe ulcerative colitis.
The manufacturer for TREMFYA is Janssen Biotech, Inc.
Johnson & Johnson maintains exclusive worldwide marketing rights to TREMFYA. For more information, visit: www.tremfya.com.
TREMFYA IMPORTANT SAFETY INFORMATION
What is the most important information I should know about TREMFYA?
TREMFYA is a prescription medicine that may cause serious side effects, including:
Serious Allergic Reactions. Stop using TREMFYA and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
o fainting, dizziness, feeling lightheaded (low blood pressure)
o swelling of your face, eyelids, lips, mouth, tongue or throat
o trouble breathing or throat tightness
o chest tightness
o skin rash, hives
o itching
Infections. TREMFYA may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA and may treat you for TB before you begin treatment with TREMFYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
o fever, sweats, or chills
o muscle aches
o weight loss
o cough
o warm, red, or painful skin or sores on your body different from your psoriasis
o diarrhea or stomach pain
o shortness of breath
o blood in your phlegm (mucus)
o burning when you urinate or urinating more often than normal
Liver problems. With the treatment of Crohn's disease or ulcerative colitis, your healthcare provider will do blood tests to check your liver before and during treatment with TREMFYA. Your healthcare provider may stop treatment with TREMFYA if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms:
o unexplained rash
o vomiting
o tiredness (fatigue)
o yellowing of the skin or the whites of your eyes
o nausea
o stomach pain (abdominal)
o loss of appetite
o dark urine
Do not use TREMFYA if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA.
Before using TREMFYA, tell your healthcare provider about all of your medical conditions, including if you:
have any of the conditions or symptoms listed in the section "What is the most important information I should know about TREMFYA?" have an infection that does not go away or that keeps coming back. have TB or have been in close contact with someone with TB. have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA. are pregnant or plan to become pregnant. It is not known if TREMFYA can harm your unborn baby.
Pregnancy Registry: If you become pregnant during treatment with TREMFYA, talk to your healthcare provider about registering in the pregnancy exposure registry for TREMFYA. You can enroll by visiting www.mothertobaby.org/ongoing-study/tremfya-guselkumab, by calling 1-877-311-8972, or emailing [email protected]. The purpose of this registry is to collect information about the safety of TREMFYA during pregnancy. are breastfeeding or plan to breastfeed. It is not known if TREMFYA passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of TREMFYA?
TREMFYA may cause serious side effects. See "What is the most important information I should know about TREMFYA?"
The most common side effects of TREMFYA include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, stomach pain, and bronchitis.
These are not all the possible side effects of TREMFYA. Call your doctor for medical advice about side effects.
Use TREMFYA exactly as your healthcare provider tells you to use it.
Please read the full Prescribing Information, including Medication Guide, for TREMFYA and discuss any questions that you have with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Dosage Forms and Strengths: TREMFYA is available as 100 mg/mL and 200 mg/2mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com
Follow us at @JNJInnovMed.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to TREMFYA. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
REFERENCES
________________________________________________
1 Bruce E. Sands, Alisa Hart, et al Efficacy of Guselkumab in Perianal Fistulizing Crohn's Disease: Week 24 Results From The Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter FUZION Study. P5691 at ACG Annual Scientific Meeting 2026. October 13 2026
2 Sulak A., et al. Where Are We and Where to Next?—The Future of Perianal Crohn's Disease Management, Journal of Clinical Medicine, Volume 12, Issue 19, October 2023, 6379, https://doi.org/10.3390/jcm12196379.
3 Spinelli A, Yanai H, Girardi P, Milicevic S, Carvello M, Maroli A, Avedano L. The Impact of Crohn's Perianal Fistula on Quality of Life: Results of an International Patient Survey. Crohns Colitis 360. 2023 Jul 25;5(3):otad036. doi: 10.1093/crocol/otad036. PMID: 37529012; PMCID: PMC10390083.
4 Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an IL-23p19 subunit-specific monoclonal antibody, binds CD64+ myeloid cells and potentially neutralizes IL-23 produced from the same cells. Poster presented at: 18th Congress of the European Crohn's and Colitis Organization (ECCO); March 1-4, 2023; Copenhagen, Denmark. Poster P504.
5 Kreuger JG, Eyerich K, Kuchroo VK. Il-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024; 15:1331217. doi:10.3389/fimmu.2024.1331217.
6 TREMFYA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
7 Skyrizi® [Prescribing Information]. North Chicago, IL: AbbVie, Inc.
8 Omvoh™ [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company.
9 National Institutes of Health: Clinicaltrials.gov. A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease (FUZION CD). Identifier: NCT05347095. https://clinicaltrials.gov/study/NCT05347095?tab=researcher. Accessed March 2026.
10 Crohn's & Colitis Foundation. Overview of Crohn's disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Accessed August 2026.
11 Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769-78.
12 Crohn's & Colitis Foundation. What is Crohn's disease? Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/causes. Accessed August 2026.
13 Crohn's & Colitis Foundation. Signs and symptoms of Crohn's disease. Available at https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-crohns-disease/symptoms. Accessed August 2026.
Společnost Johnson & Johnson uvedla, že ve studiích GALAXI 2 a GALAXI 3 dosáhlo po třech letech klinické remise až 94 % pacientů s Crohnovou nemocí léčených přípravkem TREMFYA.
New long-term data showed clinical remission rates of up to 94% and endoscopic remission rates of up to 61% in adults with moderately to severely active Crohn's disease
88% of patients achieved 90-day corticosteroid-free clinical remission
, /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new three-year data from the Phase 3 GALAXI 2 and 3 studies showing durable efficacy and a consistent safety profile for TREMFYA® (guselkumab) in adults with moderately to severely active Crohn's disease.1 The Week 144 long-term extension (LTE) results being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting reveal long-term clinical and endoscopic outcomes across both TREMFYA maintenance regimens in this chronic disease.
Clinical and endoscopic outcomes sustained through three years with TREMFYA
Patients in the GALAXI 2 and 3 studies received intravenous induction followed by one of two TREMFYA maintenance dosing regimens: 100 mg administered subcutaneously every eight weeks (q8w) or 200 mg administered subcutaneously every four weeks (q4w). At Week 144 the LTE data show:1a
94% of patients receiving TREMFYA 100 mg q8w and 91% receiving TREMFYA 200 mg q4w achieved clinical remission.b
88% of patients receiving TREMFYA 100 mg q8w and 88% receiving TREMFYA 200 mg q4w achieved 90-day corticosteroid-free clinical remission, respectively.
52% of patients receiving TREMFYA 100 mg q8w and 61% receiving TREMFYA 200 mg q4w achieved endoscopic remission.c
74% of TREMFYA-treated patients remained on treatment through three years.
Safety findings through Week 144 were consistent with the well-established safety profile of TREMFYA in Crohn's disease.1
"In a chronic, lifelong disease, the ability to sustain clinical and endoscopic outcomes through three years is particularly meaningful for patients," said David Rubin, MD, Director of the Inflammatory Bowel Disease Center at the University of Chicago.d "These results contribute to the growing body of evidence that TREMFYA can provide patients with deep and sustained remission over time, creating a strong foundation for long-term disease management."
Long-term disease control is an important need in Crohn's disease management
As Crohn's disease is a lifelong disease with no cure, patients and physicians need treatments that can provide sustained control of symptoms and intestinal inflammation over time. These results represent one of the most comprehensive three-year datasets in Crohn's disease reported to date, demonstrating durable clinical, corticosteroid-free and endoscopic remission across both TREMFYA maintenance regimens.
"Johnson & Johnson has built deep expertise in immune-mediated diseases including inflammatory bowel disease, and our research is designed to answer questions that arise over the course of this chronic condition," said David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head, Johnson & Johnson. "The clinical and endoscopic remission observed with TREMFYA through three years reinforces our commitment to generating long-term evidence that can help physicians make informed treatment decisions for people living with Crohn's disease."
TREMFYA is the only approved dual-acting monoclonal antibody in inflammatory bowel disease (IBD) that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23. IL-23 is a cytokine secreted by activated monocyte/macrophages and dendritic cells that is known to be a driver of immune-mediated diseases including UC. Findings are based on in vitro studies.2 3 4 5 6
For a full list of all Johnson & Johnson data being presented at ACG visit: https://www.jnj.com/innovativemedicine/immunology/gastroenterology.
Editor's notes:
a. The Week 144 clinical remission, 90-day corticosteroid-free clinical remission and endoscopic remission results above represent the as observed data for the three-year GALAXI analysis. The observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 144; participants who had a dose adjustment were not include
b. Clinical remission was defined as a CDAI score <150.
c. Endoscopic remission was defined as an SES-CD ≤4, with a ≥2-point reduction and no subscore >1 on any subcomponent.
d. Dr. David Rubin is a paid consultant for Johnson & Johnson. He has not been compensated for any media work.
About the GALAXI program (NCT03466411)
GALAXI is a randomized, double-blind, placebo-controlled, active-controlled (ustekinumab), global, multicenter Phase 2/3 program designed to evaluate the efficacy and safety of TREMFYA in participants with moderately to severely active Crohn's disease with inadequate response/intolerance to conventional therapies (corticosteroids or immunomodulators) and/or biologics (TNF antagonists or vedolizumab). GALAXI includes a Phase 2 dose-ranging study (GALAXI 1) and two independent, identically designed confirmatory Phase 3 studies (GALAXI 2 and 3). Each GALAXI study employed a treat-through design and includes a long-term extension period that will assess clinical, endoscopic, and safety outcomes with TREMFYA treatment through a total of five years. Patients received TREMFYA 200 mg intravenous induction at Weeks 0, 4 and 8 followed by TREMFYA 200 mg subcutaneous maintenance every 4 weeks; or TREMFYA 200 mg intravenous induction at Weeks 0, 4 and 8, followed by TREMFYA7
About Crohn's disease
Crohn's disease is one of the two main forms of inflammatory bowel disease, which affects an estimated three million Americans and an estimated four million people across Europe.89 Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet, or other environmental factors.10 Symptoms of Crohn's disease can vary, but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss, and fever. Some patients may also develop fistulas, abnormal connections between the intestine and other organs or tissues, which can be associated with pain, drainage, infection, and substantial impairment in quality of life. Currently no cure is available for Crohn's disease.11
About TREMFYA (guselkumab)
Developed by Johnson & Johnson, TREMFYA is the first fully-human, dual-acting monoclonal antibody designed to neutralize inflammation at the cellular source by blocking IL-23 and binding to CD64 (a receptor on cells that produce IL-23). Findings for the dual-acting mechanism are limited to in vitro studies that demonstrate TREMFYA binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory monocyte model. The clinical significance of this finding is not known.
TREMFYA is a prescription medicine approved in the U.S. to treat:
adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).
adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with active psoriatic arthritis.
adults with moderately to severely active ulcerative colitis.
adults with moderately to severely active Crohn's disease.
TREMFYA is approved in Europe, Canada, Japan, and a number of other countries for the treatment of adults with moderate-to-severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate-to-severe Crohn's disease and adults with moderate-to-severe ulcerative colitis.
The manufacturer for TREMFYA is Janssen Biotech, Inc.
Johnson & Johnson maintains exclusive worldwide marketing rights to TREMFYA. For more information, visit: www.tremfya.com.
TREMFYA IMPORTANT SAFETY INFORMATION
What is the most important information I should know about TREMFYA?
TREMFYA is a prescription medicine that may cause serious side effects, including:
Serious Allergic Reactions. Stop using TREMFYA and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
o fainting, dizziness, feeling lightheaded (low blood pressure)
o swelling of your face, eyelids, lips, mouth, tongue or throat
o trouble breathing or throat tightness
o chest tightness
o skin rash, hives
o itching
Infections. TREMFYA may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA and may treat you for TB before you begin treatment with TREMFYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA.
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
o fever, sweats, or chills
o muscle aches
o weight loss
o cough
o warm, red, or painful skin or sores on your body different from your psoriasis
o diarrhea or stomach pain
o shortness of breath
o blood in your phlegm (mucus)
o burning when you urinate or urinating more often than normal
Liver problems. With the treatment of Crohn's disease or ulcerative colitis, your healthcare provider will do blood tests to check your liver before and during treatment with TREMFYA. Your healthcare provider may stop treatment with TREMFYA if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms:
o unexplained rash
o vomiting
o tiredness (fatigue)
o yellowing of the skin or the whites of your eyes
o nausea
o stomach pain (abdominal)
o loss of appetite
o dark urine
Do not use TREMFYA if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA.
Before using TREMFYA, tell your healthcare provider about all of your medical conditions, including if you:
have any of the conditions or symptoms listed in the section "What is the most important information I should know about TREMFYA?"
have an infection that does not go away or that keeps coming back.
have TB or have been in close contact with someone with TB.
have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA.
are pregnant or plan to become pregnant. It is not known if TREMFYA can harm your unborn baby.
Pregnancy Registry: If you become pregnant during treatment with TREMFYA, talk to your healthcare provider about registering in the pregnancy exposure registry for TREMFYA. You can enroll by visiting www.mothertobaby.org/ongoing-study/tremfya-guselkumab, by calling 1-877-311-8972, or emailing [email protected]. The purpose of this registry is to collect information about the safety of TREMFYA during pregnancy.
are breastfeeding or plan to breastfeed. It is not known if TREMFYA passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of TREMFYA?
TREMFYA may cause serious side effects. See "What is the most important information I should know about TREMFYA?"
The most common side effects of TREMFYA include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, stomach pain, and bronchitis.
These are not all the possible side effects of TREMFYA. Call your doctor for medical advice about side effects.
Use TREMFYA exactly as your healthcare provider tells you to use it.
Please read the full Prescribing Information, including Medication Guide, for TREMFYA and discuss any questions that you have with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Dosage Forms and Strengths: TREMFYA is available as 100 mg/mL and 200 mg/2mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com
Follow us at @JNJInnovMed.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to TREMFYA. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
REFERENCES
____________________________
1 D'Haens GR, Rubin DT, et al. Efficacy and Safety of Guselkumab Through Week 96 After Intravenous or Subcutaneous Induction in Participants With Crohn's Disease: Phase 3 Long-term Extension Data From GALAXI 2 and GALAXI 3 P5693 at ACG Annual Scientific Meeting 2026. October 13 2026.
2 Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an IL-23p19 subunit-specific monoclonal antibody, binds CD64+ myeloid cells and potentially neutralizes IL-23 produced from the same cells. Poster presented at: 18th Congress of the European Crohn's and Colitis Organization (ECCO); March 1-4, 2023; Copenhagen, Denmark. Poster P504.
3 Kreuger JG, Eyerich K, Kuchroo VK. Il-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024; 15:1331217. doi:10.3389/fimmu.2024.1331217.
4 TREMFYA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
5 Skyrizi® [Prescribing Information]. North Chicago, IL: AbbVie, Inc.
6 Omvoh™ [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company.
7 Panaccione, R et al. Efficacy and safety of guselkumab therapy in patients with moderately to severely active Crohn's disease: results of the GALAXI 2 & 3 phase 3 studies. Oral presentation (Abstract #1057b) at Digestive Disease Week (DDW) 2024. May 2024.
8 Crohn's & Colitis Foundation. Overview of Crohn's disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Accessed August 2026.
9 Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769-78.
10 Crohn's & Colitis Foundation. What is Crohn's disease? Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/causes. Accessed August 2026.
11 Crohn's & Colitis Foundation. Signs and symptoms of Crohn's disease. Available at https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-crohns-disease/symptoms. Accessed August 2026.
Disney jmenoval Karandeepa Ananda prvním CTO pro celou společnost, který povede technologickou transformaci s cílem lépe konkurovat Netflixu a YouTube ve streamingu.
You're currently following this author!
Click to unsubscribe from email alerts.
Disney hired Karandeep Anand from Character.AI to oversee its technology strategy.
Manaure Quintero / AFP via Getty Images; Illustration by Samuel Boivin/NurPhoto via Getty Images
Disney's new tech chief said in a memo to employees that he "won't pretend it will be easy" to win in the changing media environment.
Karandeep Anand, the Mouse House's first-ever companywide CTO, was hired by CEO Josh D'Amaro to lead Disney's tech transformation. He started in early October. Under D'Amaro, Disney is investing in tech to better compete with Netflix and YouTube in streaming.
Anand previously ran Character.AI, an AI startup that Disney sent a cease-and-desist letter to last fall. (Disney told Character.AI not to make chatbots from its copyrighted characters without permission, and the startup complied.)
Anand told staffers on Friday afternoon that the media business is "at an inflection point," adding that he's confident Disney has a strong hand thanks to its deep, iconic content library and a passionate fan base.
"With our rich IP and global fan community, I strongly believe we are uniquely positioned to win," Anand said in his memo, which was obtained by Business Insider.
The new tech chief said that winning in this highly competitive media landscape "will take focus, speed, and the willingness to say no to good ideas so we can say yes to great ones."
Anand also said he's "admired Disney for as long as I can remember" and said he had constructive conversations in his first full week inside the Mouse House.
"What stands out most is the talent and care this team puts into its work, the craft Disney has perfected, and the strong foundation you've built," Anand said.
Disney has leaned into tech this year by embracing AI and further unifying Disney+ and Hulu — the first step in building a streaming super app that includes games and merchandise.
Anand highlighted the same three top priorities that D'Amaro listed in the memo announcing his hire: great storytelling as our North Star, technology in service of creativity, and operating as One Disney.
D'Amaro is contending with Disney's listless stock price. Shares have fallen more than 1% in the past year, compared to a 17.3% gain for the S&P 500, and are down over 38% in the past five years, while US stocks broadly have risen more than 74%.
Read Anand's full memo below:
Team,As I close out my first week at Disney, thank you for the warm welcome you gave me and the colleagues who joined me.I've admired Disney for as long as I can remember, so walking the lot, attending the Tech Showcase, and meeting so many of you has been an unforgettable start. What stands out most is the talent and care this team puts into its work, the craft Disney has perfected, and the strong foundation you've built.It's only been a few days, but I'm more excited than when I accepted this job. Josh has laid out three priorities: great storytelling as our North Star, technology in service of creativity, and operating as One Disney. Our job in technology is to make those real, and the possibilities are enormous. We're at an inflection point in the tech and media industry, and with our rich IP and global fan community, I strongly believe we are uniquely positioned to win.I won't pretend it will be easy. It will take focus, speed, and the willingness to say no to good ideas so we can say yes to great ones. I'll be direct with you about priorities and tradeoffs as I learn them. But I'm confident we can get there, and do it quickly.Over the coming weeks I'll be meeting with teams across the company, and I look forward to sharing how I'm thinking about our priorities soon. Until then, please keep doing the great work you're doing.Thank you again. I'm glad and privileged to be on this team.Karan
Read next
James Faris
You're currently following this author!
Click to unsubscribe from email alerts.
James Faris is a media correspondent in New York City.He covers the business of media & entertainment, specifically the streaming, TV, and AI strategies of Hollywood giants like Disney, Skydance (Paramount-WBD), and Netflix. He previously wrote about the stock market, the economy, and real estate.James joined Business Insider after graduating magna cum laude from James Madison University.Email James at [email protected] and follow him on LinkedIn.
GE Aerospace, Shield AI a WZL-2 podepsaly memorandum o porozumění, které prověří možnosti údržby, oprav a generálních oprav motorů F110 pro autonomní letoun X-BAT v Polsku; očekávané tržby nezveřejnily.
The next frontier of artificial intelligence may not be another data center, but a fighter aircraft that can operate without a runway. GE Aerospace (NYSE:GE) is positioning its engine technology alongside Shield AI’s autonomous aircraft ambitions, creating a potential new defense opportunity as militaries explore ways to deploy AI-powered airpower beyond traditional infrastructure.
• GE Aerospace stock is holding steady today. What’s the outlook for GE shares?
GE Enters the Autonomous Fighter PushOn Oct. 12, GE Aerospace, Shield AI and Poland’s Wojskowe Zakłady Lotnicze Nr 2 (WZL-2) signed a memorandum of understanding to explore maintenance, repair and overhaul capabilities in Poland for GE’s F110 engine powering Shield AI’s X-BAT aircraft.
The announcement covers the engine and its Axisymmetric Vectoring Exhaust Nozzle, which enables thrust vectoring for vertical takeoff and landing. The companies will assess the facilities, equipment and training needed to establish local maintenance capabilities.
X-BAT is designed to take off and land vertically, potentially allowing it to operate from roads, ships and smaller sites instead of conventional runways. That flexibility could matter on NATO’s eastern flank, where airfields could be vulnerable during a conflict.
Shield AI brings the autonomous flight technology; GE supplies the propulsion system and engine-support expertise. GE is not developing the aircraft’s AI pilot, but its technology is part of the physical infrastructure needed to make the aircraft operational.
Read Next
The AI Opportunity Beyond Data CentersFor GE investors, the potential opportunity lies in the hardware and services behind autonomous systems. AI-enabled aircraft still require propulsion, specialized components, repairs and maintenance — areas where established aerospace suppliers could benefit if new platforms progress from development to deployment.
GE’s F110 engine has accumulated more than 11 million flight hours over four decades of continuous production and improvement, according to the company. Its experience gives GE an established role in the program, while the thrust-vectoring nozzle is designed to support X-BAT’s vertical flight capability.
The partnership also builds on a September letter of intent involving Shield AI, Poland’s state-owned defense group PGZ and WZL-2 to explore X-BAT design, production and delivery in Poland. The latest agreement extends that ambition to potential in-country engine support.
What It Means for GE StockThe distinction between strategic positioning and financial impact remains important. The memorandum is an agreement to explore maintenance capabilities, not a confirmed engine order or a guarantee that a Polish facility will be established. The companies have not disclosed expected revenue from the arrangement.
For GE, the opportunity depends on X-BAT advancing toward deployment and generating demand for engines, repairs and long-term sustainment. Investors should watch for firm contracts, production milestones and evidence that the program can translate into incremental business.
Investment takeaway: Shield AI is giving GE Aerospace a potential role in the infrastructure behind autonomous warfare, extending its exposure to AI beyond the data center boom. But until the partnership produces firm orders or measurable revenue, it remains a strategic opportunity rather than a material earnings catalyst.
Read Next
Photo: Officials from the companies sign the MOU, Photo courtesy GE Aerospace
The latest quote sits approximately 1.2% below Stephen Rusckowski's disclosed September entry. Summary
Insider buying supplies conviction, but Oracle’s infrastructure returns still require operating evidence.
Oracle ORCL, the enterprise-software and AI-cloud provider, trades at $137.745, down about 2.6% at 12.34pm EST on October 12 and roughly 1.2% below a director's recent purchase price. A nearly $3.5 million insider investment adds conviction to the story. It does not settle the bigger question: how much cash Oracle's AI infrastructure push will ultimately generate.
An October 1 SEC filing shows that director Stephen Rusckowski's living trust bought 25,000 shares on September 29 at a weighted average of $139.352. That works out to $3,483,800 based on the reported average. Barron's describes the transaction as his first open-market purchase since joining Oracle's board. The valuation snapshot places shares 29.51% below the $195.40 GF Value estimate, suggesting potential upside if the business delivers on those expectations.
That discount deserves attention. So does the execution risk. A director's purchase offers a vote of confidence, while a valuation estimate offers a benchmark; neither guarantees a return. Investors still need to watch infrastructure utilization, customer payments and the cash earned against the money spent building capacity. Oracle's next test is turning AI demand into durable cash flow.
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
The 10-year U.S. Treasury note rarely looks this appealing. Its yield reached 5.22% on Oct. 8, according to Federal Reserve data, the highest reading since March 2002. Costco Wholesale (COST +1.32%) offers a forward dividend yield of 0.6%.
Put $10,000 into each, and the Treasury hands you payouts of about $520 a year while Costco sends you around $60. Why bother?
But income is only one piece of an investment's return, and for long-term investors, it's often a small part.
Premium Feature
Moneyball Superscore
83/100
Today's Change
(
1.32
%) $
12.52
Current Price
$
959.44
The hot dog doesn't get bigger Like Costco's famous hot dog and soda combo (still $1.50 after 41 years), Treasury coupons have a fixed value. A 10-year note's coupon rate is locked for 10 years. The interest you receive in 2036 will match next spring's payment to the penny, even after a decade of inflation.
Hold to maturity, and you get your original $10,000 back; it'll just buy less stuff than it does today. The coupon payouts you receive along the way will help, assuming the rate you locked in remains ahead of average inflation.
Rate changes only matter if you sell your Treasuries before maturity. No one will pay full price for your note if new Treasuries offer better rates, but your note will gain value when rates go down.
But Costco's dividend has grown 13.2% per year over the last five years. The company also has a habit of surprising shareholders with special dividends, such as the $15-per-share dividend it paid in January 2024. That one-time payment was roughly equivalent to 15 of the regular quarterly payouts at the time.
The business behind the stock Stocks let you own a small piece of an actual business. People work hard to increase the corporation's value, which over time lifts the stock price. No empire lasts forever, but Costco's story started decades ago, and it's still a market-beating growth stock.
Costco generated $303.2 billion in sales over the past 12 months, up 10.1% year over year. Earnings per share rose 13.9% over the same period. The company keeps markups low, with a gross margin of just 12.8%, and earns a large share of its operating profit from membership fees.
As a result, $10,000 invested in Costco stock 10 years ago would be worth $63,340 today. With reinvested dividends, you're looking at $74,980 instead:
COST data by YCharts
10-year Treasury notes yielded about 1.8% in October 2016. A $10,000 investment would pay out $11,800 in total over the same decade. That's your original $10,000 plus $1,800 in coupon payouts. Treasuries bought today will pay out roughly $5,200 over the next 10 years (plus the $10,000 return of principal), but that's still a forgettable gain next to Costco's long-term returns.
The catch Costco's stock isn't cheap, exposing investors to valuation risk. It trades at 46 times trailing earnings and 38.2 times forward estimates, which is a rich price for a company expected to grow earnings about 9.7% annually.
The stock gained just 2.8% over the past year, trailing the Treasury's yield, and sits 12.8% below its 52-week high as of Oct. 12.
Image source: The Motley Fool.
Pick your cart If you need reliable income soon, the Treasury is a fine choice at 5.2%. But if you don't need the money for the next 10 years, Costco offers a few things that the Treasury note can't: a business that keeps growing, a dividend that keeps rising, and a long record of turning patient money into a much bigger pile.
Morgan Stanley označila eBay za svůj hlavní tip, zvýšila cílovou cenu akcií na 132 USD a očekává, že živé prodeje budou představovat více než 40 % růstu společnosti.
Morgan Stanley sees live selling driving more than 40% of eBay's growth Summary
Morgan Stanley named eBay a top pick, raised its target to $132 from $127 and kept Overweight, citing live selling as an underappreciated growth engine.
eBay EBAY rose 3.50% as of 1:00 p.m. ET after Morgan Stanley named it a top pick and raised its price target to $132 from $127, keeping an Overweight rating. Analyst Nathan Feather said eBay's acceleration in gross merchandise volume had come as a surprise, and argued that live selling is a bigger growth engine than the Street has appreciated.
Morgan Stanley estimated that live selling could account for more than 40% of eBay's growth, and forecast compound annual growth of about 22% for that business through 2030. The call builds on what eBay reported in August. Second-quarter GMV rose 15% on an as-reported basis to $22.4 billion, and GMV on eBay Live grew roughly eightfold year over year across its seven markets.
On the other hand, Wells Fargo cut its target to $91 from $92 and kept an Underweight rating, warning that investment in live selling and competition could weigh on earnings growth.
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
